Menu

Combivair Forte

DESCRIPTION

Combivair Forte Rotacap is a combination of budesonide, a potent glucocorticoid and formoterol, a selective long-acting beta 2 -agonist.  Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity. Formoterol is a very potent long-acting beta 2-agonist with a high intrinsic activity and a rapid onset of action.

COMPOSITION

Combivair Forte Rotacap: 

Each capsule contains: 

Budesonide 400mcg

Formoterol Fumarate (as Dihydrate) 12mcg 

INDICATIONS

Combivair Forte Rotacap is indicated in the regular treatment of asthma, where use of a combination (long-acting beta -agonist and inhaled 2 corticosteroid) has been found to be appropriate. Symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) with a history of repeated exacerbations despite regular therapy with long-acting bronchodilators. It is not indicated for the relief of acute bronchospasm.

DOSAGE AND ADMINISTRATION

Capsules are intended for use through Revolizer or Rotaflo only and are not to be swallowed. Dosage is individual and adjusted according to disease severity. When control has been achieved, the dose should be titrated to the lowest effective dose, which could include Combivair Forte Rotacap given once daily.

CONTRAINDICATIONS

Combivair Forte Rotacap is contraindicated in patients with a history of hypersensitivity to any of the component of the drug product.

PRESENTATION

Combivair Forte Rotacaps: Blister pack of 3 X 10’s rotacaps

Patients should consult with their physician before taking any medicine.

Sprahaler Respules

DESCRIPTION

SPRAHALER RESPULES is an anticholinergic agent, and it is used for the treatment of Asthma and COPD.

COMPOSITION

Ipratropium Bromide BP equivalent to Ipratropium Bromide (Anhydrous) 500mcg
Isotonic solution q.s.

INDICATIONS

Sprahaler Respules administered either alone or with other bronchodilators, especially beta-adrenergic, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.
Sprahaler Respules is indicated, when used concomitantly with inhaled beta2-agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.

DOSAGE AND ADMINISTRATION

Adults:
500 mcg (in 2 mL respules) 3 to 4 times daily
Children (6-12 years):
250 mcg (1 mL) up to 4 times daily
Children (below 6 years):
125 to 250 mcg (0.5 to 1 mL) up to 4 times daily

CONTRAINDICATIONS

Ipratropium bromide is contraindicated in known or suspected cases of hypersensitivity to ipratropium bromide, or to atropine and its derivatives.

UNDESIRABLE EFFECTS

The most common non-respiratory adverse reactions reported in clinical trials are headache, throat irritation, cough, gastrointestinal motility disorders (including constipation, diarrhea and vomiting), nausea (with or without vomiting), dizziness and dryness of the mouth.

PRESENTATION

Sprahaler Respules is available as respules of 2mL

PREGNANCY AND LACTATION

Pregnancy Category B. No adequate or well-controlled studies have been conducted in pregnant women. Because animal reproduction studies are not always predictive of human response, ipratropium bromide should be used during pregnancy only if clearly needed. It is not known whether ipratropium bromide is excreted in human milk. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that the active component, ipratropium bromide, would reach the infant to an important extent, especially when inhaled. However, because many drugs are excreted in human milk, caution should be exercised when ipratropium bromide is administered to a nursing mother.

Patients should consult with their physician before taking any medicine.

 

Pirfenox 200mg

DESCRIPTION

Pirfenox tablets contain the active substance pirfenidone which is used for the treatment of mild-to-moderate idiopathic pulmonary fibrosis (IPF) in adults. IPF is a condition in which the tissues of lungs become swollen and scarred over time and, as a result, it becomes difficult to breathe deeply. This makes it hard for the lungs to work properly. Pirfenox helps to reduce scarring and swelling in the lungs and helps the patient to breathe better.

COMPOSITION

Each film-coated tablet contains:

Pirfenidone 200mg

INDICATIONS

  • Idiopathic pulmonary fibrosis (IPF)

DOSAGE AND ADMINISTRATION

Start with a 200 mg dose given three times a day (600 mg/day). After 2 weeks, gradually increase the dose by 200 mg at a time. It is desirable to maintain or achieve a final dose of 800 mg at a time (2,400 mg/day).

CONTRAINDICATIONS

  • Drug hypersensitivity
  • Concomitant use of fluvoxamine
  • Severe liver or kidney disease

PRESENTATION

Pirfenox 200mg tablets:

Alu-Alu Blister of 3 X 10’s

Alu-Alu Blister of 5 X 10’s

 

Patients should consult with their physician before taking any medicine.

 

Foracort HFA Inhaler

DESCRIPTION

Foracort HFA Inhaler is a combination of budesonide, a potent glucocorticoid, and formoterol fumarate dihydrate, a selective, long-acting beta2-agonist, which have different modes of action and show additive effects in terms of reduction of asthma exacerbations.

COMPOSITION

Foracort HFA Inhaler 100

Each actuation contains:

Formoterol Fumarate Dihydrate 6mcg

Budesonide 100mcg

Suspended in propellant HFA 134a q.s.

Foracort HFA Inhaler 200

Each actuation contains:

Formoterol Fumarate Dihydrate 6mcg

Budesonide 200mcg

Suspended in propellant HFA 134a q.s.

INDICATIONS

  • Asthma 
  • COPD

DOSAGE AND ADMINISTRATION

Asthma

       For Foracort inhaler there are two treatment approaches:

 

  1. Maintenance Therapy: Foracort Inhaler is taken as regular maintenance treatment with a separate rapid acting bronchodilator as rescue.

 

Foracort HFA Inhaler 100 & 200:

 

Adults (18 Years and Older)

    • 1–2 inhalations, twice daily
    • Maximum dose is 4 inhalations, twice daily

Adolescents (12-17 Years) 

    • 1–2 inhalations, twice daily 
  1. Single Maintenance and Reliever Therapy: Foracort Inhaler is taken as regular maintenance and as needed in response to symptoms.

Foracort HFA Inhaler 100 & 200:

 

Adults (18 Years and Older)

2 inhalations per day as maintenance therapy

COPD (Chronic Obstructive Pulmonary Disease):

Foracort HFA Inhaler 200:

 2 inhalations per day as maintenance therapy 

CONTRAINDICATIONS

  • Patients with a history of hypersensitivity to any of the components of the drug product.
  • Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.
  • Relief from acute bronchospasm

 

UNDESIRABLE EFFECTS

Since Foracort HFA Inhaler contains both budesonide and formoterol, the same pattern of undesirable effects as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds. The most common drug related adverse reactions are pharmacologically predictable side-effects of beta2-agonist therapy, such as tremor and palpitations. These tend to be mild and usually disappear within a few days of treatment.

PRESENTATION

Foracort HFA Inhaler is available in a canister containing 120 metered doses

Patients should consult with their physician before taking any medicine.

Rotaflo

DESCRIPTION

Rotaflo is a plastic inhalation device which is breath activated. This means when you inhale, the Rotaflo releases medication from the Rotacap.

INDICATIONS

Rotaflo is an easy-to-use and a preferred device in patients with mild asthma and COPD, as well as in healthy participants with no previous experience of using inhalation devices.

DOSAGE AND ADMINISTRATION

Dry Powder Inhalation capsules are intended for use through Rotaflo only and are not to be swallowed. 

Key Features

  • Does not require coordination between inhalation and actuation
  • Easy to learn, remember and to teach how to use correctly
  • High drug deposition 
  • Accurate, consistent and effective in delivering medication to the lungs 
  • Portable
  • Visually appealing to the patient

 

PRESENTATION

 Rotaflo: Pack of 1’s

Patients should consult with their physician before taking any inhaler device.

 

 

Revolizer

DESCRIPTION

Revolizer is a novel DPI device, which has been designed and developed to address the critical requirements of an ideal inhalation device. It provides accurate dosing and excellent lung deposition even at low inspiratory flow rates and is very easy to use and maintain.

INDICATIONS

Revolizer is an easy-to-use and a preferred device in patients with mild asthma and COPD, as well as in healthy participants with no previous experience of using inhalation devices.

DOSAGE AND ADMINISTRATION

Dry Powder Inhalation capsules are intended for use through Revolizer only and are not to be swallowed. 

KEY FEATURES

  • Does not require coordination between inhalation and actuation.
  • Easy to learn, remember and to teach how to use correctly.
  • High drug deposition across various inspiratory flow rates (as low as 30L/min)
  • Accurate, consistent and effective in delivering medication to the lungs 
  • Portable- the pouch snugly fits into the pocket.
  • Transparency helps provide visual confirmation of the dose being administered.
  • Robust.
  • Visually appealing to the patient.

PRESENTATION

 Revolizer: Pack of 1’s.

Patients should consult with their physician before taking any inhaler device.

Prospan

DESCRIPTION

Prospan contains 0.84g of ivy leaves dry extract (5-7.5:1). It is a herbal cough syrup used to treat catarrhal disease of respiratory tract, by its secretolytic, broncho-spasmolytic and cough relieving effects.

COMPOSITION

120mL solution contain 0.84g of ivy leaves dry extracts (5-7.5:1), Potassium Sorbate (preservative), anhydrous citric caid, xanthan gum, flavouring, sorbitol solution 70% (crystallizing), purified water, 2.5mL solution contain 0.963g of the sugar substitute sorbitol = 0.08BU.

INDICATIONS

Prospan cough syrup is used to improve symptoms of chronic-inflammatory bronchial disease of the respiratory tract accompanied by coughing. 

DOSAGE AND ADMINISTRATION

Age                                                                     Dose

Children below 6 years of age                         2.5 mL, 2 times daily

Children 6 – 12 years of age                           5 mL, 2 times daily

Children over 12 years and adults                  2.5 mL, 2 times daily

PRESENTATION

Prospan cough syrup is a light brown, slightly cloudy syrup and available in original pack of 120mL solution.

Rabecid

DESCRIPTION

The active ingredient contains in Rabecid Tablets is Rabeprazole Sodium, which is substituted benzimidazole that inhibits gastric secretion. 

INDICATIONS

Rabecid is proton pump inhibitor indicated in adults for:

  • Treatment of non-erosive and erosive gastroesophageal reflux disease
  • Esophageal complication of reflux disease (Peptic stricture or Barrett’s esophagus)
  • Erosive esophagitis or esophageal Complications
  • Maintenance of healing of erosive or ulcerative GERD
  • Healing of gastric and duodenal ulcer 
  • Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence 
  • Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
  • H. Pylori associated Ulcer.

DOSAGE AND ADMINISTRATION

Rabecid tablets should be swallowed whole. Should not be chewed, crushed, or split. 

Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease/GERD.

20 mg once daily.

Maintenance of Healing of Erosive or Ulcerative GERD.

20mg once daily.

Treatment of Symptomatic GERD.

20 mg once daily.

Healing of Gastric and Duodenal Ulcers.

20mg once daily before morning meal.

Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence.

Three Drug Regimen

All three medications Rabecid 20mg, Amoxicillin 1000mg, Clarithromycin 500mg should be taken twice daily with morning and evening meals for 7 days.

Treatment of Pathological Hypersecretory Conditions. Including Zollinger-Ellison Syndrome

Starting dose 60 mg once daily then adjust to patient needs.

PRESENTATION

Rabecid 10mg enteric-coated tablets: Blister pack of 1 X 14’s

Rabecid 20mg enteric-coated tablets: Blister pack of 1 X 14’s

 Patients should consult with their physician before taking any medicine.

Airtal ER

DESCRIPTION:

Airtal ER is a non-steroidal agent with excellent anti-inflammatory and analgesic properties.

COMPOSITION:

Airtal 200 mg ER film coated tablet contains aceclofenac 200 mg

INDICATIONS:

Airtal is indicated in the management of acute and chronic painful and inflammatory processes such as rheumatoid arthritis, osteoarthritis, arthrosis, ankylosing spondylitis, cervicalgia, lumbago, tendinitis, sprains and scapulo-humeral periarthritis. Airtal is also indicated in the treatment of painful processes of various etiologies such as odontalgia, lumbosciatica, myalgia, post-episiotomy pain, postlabour pain, and primary dysmenorrhea.

DOSAGE & ADMINISTRATION:

The recommended daily dose is one tablet every 12 hours (200 mg/day). Tablets should be taken with a little water. Dosage in hepatic impairment: The dose should be reduced to 100 mg daily in patients with hepatic impairment.

CONTRAINDICATIONS:

Aceclofenac should not be administered to patients with gastrointestinal bleeding or with active or suspected peptic ulcer.

UNDESIRABLE EFFECTS:

The majority of side effects observed, have been mild and reversible and include gastrointestinal disorders (flatulence, abdominal pain, nausea and diarrhoea) and occasional occurrence of dizziness. Dermatological complaints, including pruritus and rash, as well as abnormal hepatic enzyme levels and raised serum creatinine, have occasionally been reported.

PRESENTATION:

Airtal 200mg ER tablets: Pack of 10’s X 1 tablets

Patients should consult with their physician before taking any medicine.

Xormet XR

DESCRIPTION:

XORMET XR (Metformin HCl Extended Release) is an oral anti-diabetic medicine that belongs to the group of biguanides.

Metformin, the active ingredient in XORMET XR, reduces hepatic glucose production, increases insulin sensitivity in muscles and delays intestinal glucose absorption.

COMPOSITION:

XORMET XR 500mg: Each extended release tablet contains Metformin HCI B.P. 500mg. XORMET XR 1000mg: Each extended release tablet contains Metformin HCI B.P. 1000mg.

INDICATIONS:

XORMET XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

DOSAGE & ADMINISTRATION:

XORMET XR should be taken once daily with the evening meal. The dosage of XORMET XR must be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended daily dose of 2000 mg. The starting dose of XORMET XR in patients who are not currently taking metformin is 500 mg once daily, with the evening meal. The dose can be up titrated in 500 mg increments no sooner than every 1-2 weeks if a higher dose of XORMET XR is needed and there are no gastrointestinal adverse reactions. If XORMET XR is considered appropriate for a patient already receiving immediate-release metformin, the patient can be switched to XORMET XR once daily at the same total daily dose, up to 2000 mg once daily. XORMET XR tablets must be swallowed whole and never split, crushed or chewed. If a dose of XORMET XR is missed, patients should be cautioned against taking two doses of 2000 mg the same day. Resume dosing as according to prescribing recommendations. Co-administration of XORMET XR with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.

CONTRAINDICATIONS:

METFORMIN is contraindicated in patients with: • Renal impairment (e.g., serum creatinine levels ≥ 1.5 mg/dl for men, ≥ 1.4 mg/dl for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. Known hypersensitivity to metformin hydrochloride. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin.

UNDESIRABLE EFFECTS:

The reported adverse effects of metformin are Diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort (abdominal pain & abdominal distention), headache, abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation, constipation, dyspepsia, heart burn, dizziness & upper respiratory tract infection. Patient may have taste disturbances, there may be a weight loss. Skin reactions have been reported rarely. Hypoglycemia is rare with biguanide given alone, although it may occur if other contributing factors or drugs are present.

PRESENTATION:

XORMET XR 500mg tablets: Blister pack of 5 x 10’s tablet. XORMET XR 1000mg tablets: Blister pack of 5 x 10’s tablet.

PREGNANCY & LACTATION:

Lactic acidosis can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic insufficiency, renal impairment, and acute congestive heart failure. The symptoms include malaise, myalgia’s, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap and elevated blood lactate. If acidosis is suspected, discontinue XORMET XR and hospitalize the patient immediately. · Conditions associated with hypoxia, such as acute heart failure, recent myocardial infarction. or shock, may increase the risk of lactic acidosis. · Care should be taken in patients with renal impairment. Renal function should be monitored throughout the therapy. If renal dysfunction is anticipated particularly in elderly patients, renal function should be assessed more frequently and drug should be discontinued if evidence of renal impairment is present as it may increase the chance of lactic acidosis. Dehydration may contribute to renal impairment. · Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake while receiving XORMET XR. · XORMET XR should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. · Driving: Diabetes Mellitus, its complications and the medications used to treat it, may affect a patient’s’ ability to drive safely. · Owing to the possibility of decreased vitamin B12 absorption, annual monitoring of vitamin B12 concentrations is advisable during long term treatment. · Safety and effectiveness of METFORMIN in pediatric patients under 18 years has not been established. · May also need to be temporarily stopped for examinations using contrast media in some patients (intravascular administration of iodinated contrast materials in radiologic studies can lead to renal failure, metformin should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal). · Should be discontinued in patients undergoing surgery and only restarted once normal renal function has been established.

Patients should consult with their physician before taking any medicine.

Diajard-MXR

BRAND NAME:

Diajard-MXR

GENERIC NAME:

Empagliflozin + Metformin HCI Extended-release

DESCRIPTION:

Diajard-MXR (Empaglifozin+Metformin extended release) is a prescription medicine used to: Diabetes Mellitus Type-2

PRECATIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.

DOSAGE & ADMISITRATION:

Take Diajard-MXR (empagliflozin and metformin) orally once daily with a meal in the morning. Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin hydrochloride 2000mg and empagliflozin 25mg

INDICATIONS:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

It is contraindicated in patients with moderate to severe renal impairment (eGFR less than 45 mL/min/1.73 m2 ), end stage renal disease, or dialysis. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin

ADVERSE EVENTS:

The reported adverse events are; hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, increased low-density lipoprotein cholesterol, urinary tract infection (asymptomatic bacteriuria, cystitis), female genital mycotic infection

PRESENTATION:

Diajard-MXR is presented in , 5/1000, 10/1000, 12.5/500 or 25/1000 mg  

STORAGE:

Do not store above 30°C,keep in dry place, protect from light.

 Patient should consult with their physician before taking any medicine

Diajard-M

BRAND NAME:

Diajard-M

GENERIC NAME:

Empagliflozin + Metformin HCI

DESCRIPTION:

Diajard-M (Empaglifozin+Metformin) is a prescription medicine used to: Diabetes Mellitus Type-2

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.

DOSAGE & ADMINISTRATION:

Take Diajard-M (empagliflozin and metformin) twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin. Adjust dosing based on effectiveness and tolerability while not exceeding the maximum recommended daily dose of metformin hydrochloride 2000mg and empagliflozin 25mg.

INDICATIONS:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

Patients with history of serious hypersensitivity reaction to empagliflozin or any of the excipients. Patients with severe renal impairment, end-stage renal  disease, or dialysis.

ADVERSE EVENTS:

The reported adverse events are; hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, increased low-density lipoprotein cholesterol, urinary tract infection (asymptomatic bacteriuria, cystitis), female genital mycotic infection

PRESENTATION:

Diajard-M is presented in 5/500, 5/1000, 12.5/500 or 12.5/1000  

STORAGE:

Do not store above 30°C,keep in dry place, protect from light

Patient should consult with their physician before taking any medicine.

Diajard

BRAND NAME:

Diajard

GENERIC NAME:

Empagliflozin

DESCRIPTION:

Diajard (Empagliflozin) is a prescription medicine used to treat:

Diabetes Mellitus Type-2

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.

DOSAGE & ADMINISTRATION:

The recommended dose of Diajard (Empagliflozin) is 10 mg once daily in the morning, taken with or without food, increased to 25 mg once daily if necessary and if tolerated.

INDICATIONS:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

Patients with history of serious hypersensitivity reaction to empagliflozin or any of the excipients. Patients with severe renal impairment, end-stage renal  disease, or dialysis.

ADVERSE EVENTS:

The reported adverse events are; hypotension, ketoacidosis, acute kidney injury and impairment in renal function, urosepsis and pyelonephritis, hypoglycemia with concomitant use with insulin and insulin secretagogues, necrotizing fasciitis of the perineum (Fournier’s gangrene), genital mycotic infections, hypersensitivity reactions, increased low-density lipoprotein cholesterol, urinary tract infection (asymptomatic bacteriuria, cystitis), female genital mycotic infection

PRESENTATION: 

Diajard is presented in 10 mg & 25 mg tablets

STORAGE: 

Do not store above 30°C,keep in dry place, protect from light

Patient should consult with their physician before taking any medicine.

Tagipmet XR

BRAND NAME:

Tagipmet XR

GENERIC NAME:

Sitagliptin + Metformin HCI Sustained Release

DESCRIPTION:

Tagipmet-XR(Sitagliptin+Metformin extended release) is a prescription medicine used to treat:

Diabetes Mellitus Type-2

PRECATIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.

DOSAGE & ADMINISTATION:

The dosage of Tagipmet-XR should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin.

INDICATIONS:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

Tagipmet XR (Sitagliptin and Metformin Hydrochloride Sustained Release) is contraindicated in patients with: Renal impairment or renal dysfunction (e.g., serum creatinine levels greater than or equal to 1.5 mg/dL for men, greater than or equal to 1.4 mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute septicemia. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. 

ADVERSE EVENTS:

The reported adverse effect includes Diarrhea, Upper Respiratory tract infections, headache, dizziness and gastrointestinal disturbances (anorexia, nausea, vomiting and abdominal pain), flatulence, hypoglycemia, peripheral oedema

PRESENTATION: 

TAGIPMET XR is presented in 50/500, 50/1000 & 100/1000 respectively

STORAGE:

Do not store above 30°C,keep in dry place, protect from light

Patient should consult with their physician before taking any medicine.

Hitica

Brand Name:

HITICA

Generic Name:

Ticagrelor

Description:

HITICA is a prescription medicine used to reduce the rate of cardiovascular death, heart attack, and stroke in patients with the acute coronary syndrome (ACS) or a history of myocardial infarction (MI) & to reduce the rate of stent thrombosis in patients who have been stented for treatment of ACS.

Composition:

Ticagrelor

Indications:

ACS patients on the prescription of a doctor

Dosage & Administration:

Take HITICA twice a day. Your doctor may change your dose of HITICA during treatment. 

If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time.

Contraindications:

HITICA is contraindicated in patients with a history of intracranial hemorrhage, and in patients with active pathological bleeding such as a peptic ulcer or intracranial hemorrhage. It is also contraindicated in patients with hypersensitivity (e.g., angioedema) to ticagrelor or any component of the product. 

Presentation:

Hitica 60mg, Hitica 90mg film-coated tablets: Alu-Alu Blister Pack of 1×10 tablets.

Apiban

Brand Name:

 Apiban 

Generic Name:

Apixaban 

Description:

Reduce the  risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE). In patients who have undergone hip or knee replacement surgery. For the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy 

Composition:

Apixaban 

Indications:

Nonvalvular Atrial Fibrillation. Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), 

Hip Or Knee Replacement Surgery, Recurrent DVT and PE

Dosage & Administration:

Oral administration of 2.5 mg twice daily or 5 mg twice daily.

Contraindications:

Patients having Active pathological bleeding or Severe hypersensitivity reaction to APIBAN (Apixaban). Pregnant women, Lactating Mothers & patients having severe Hepatic Impairment. If you are taking P-gp and strong CYP3A4 inducers, have Prosthetic heart valves, Spinal/Epidural Anesthesia or Puncture, Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy, Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome

Presentation:

2.5 mg and 5 mg in Blister Pack of 3×10’s tablets

Pidogrel-AP

BRAND NAME:

Pidogrel and Pidogrel-AP

GENERIC NAME:

Clopidogrel & Clopidogrel + Aspirin

DESCRIPTION:

Clopidogrel & Clopidogrel + Aspirin are inhibitors of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

COMPOSITION:

Clopidogrel & Clopidogrel + Aspirin

INDICATIONS:

Pidogrel is a P2Y12 platelet inhibitor indicated for Acute coronary syndrome and recent myocardial infarction

DOSAGE AND ADMINISTRATION:

Pidogrel 75mg,  Pidogrel-AP 75mg (75mg/75mg) & Pidogrel-AP 150mg (75mg/150mg) once daily

CONTRAINDICATIONS:

Active pathological bleeding, such as a peptic ulcer or intracranial hemorrhage

Hypersensitivity to clopidogrel or any component of the product

PRESENTATION:

Pidogrel 1 x 10`s, Pidogrel-AP 75mg (75mg/75mg) and Pidogrel-AP 150mg (75mg/150mg) 1 x 10`s

Blokium DIU

Brand Name:

BLOKIUM & BLOKIUM DIU

Generic Name:

Atenolol & Atenolol + Chlorthalidone

Description:

Blokium and Blokium DIU is a prescription medicine. Blokium is indicated for the management of hypertension and angina pectoris and Blokium DIU is indicated for hypertension management.

Composition: 

Atenolol & Atenolol + Chlorthalidone

Indications:

Hypertensive patients and patients with angina pectoris on the prescription of a doctor

Dosage & Administration:

Blokium; 50-100 mg once a day

Contraindications:

If the patient has bronchospastic disease, heart block, or untreated cardiac failure

Presentation:

Blokium 100mg: Blister Pack of 2×10. Blokium 50mg: Blister Pack of 3×10. Blokium 25mg: Blister Pack of 3X10. Blokium DIU 100: Blister pack of 2×10. Blokium DIU 50: Blister pack of 2×10.

Misar AM

BRAND NAME:

Misar AM

GENERIC NAME:

Telmisartan + Amlodipine

DESCRIPTION:

Misar AM is a prescription medicine used with or without other antihypertensive agents or can be used as Initial therapy in uncontrolled hypertensive patients.

COMPOSITION:

Telmisartan + Amlodipine

INDICATIONS:

Uncontrolled Hypertension

DOSAGE AND ADMINISTRATION:

Misar AM 40mg/5mg, 40mg/10mg, 80mg/5mg, and 80mg/10mg once daily 

CONTRAINDICATIONS:

Avoid fetal or neonatal exposure, and hypotension (correct any volume or salt depletion before initiating therapy. Avoid concomitant use with ACE inhibitors or angiotensin receptor blockers.

PRESENTATION:

Misar AM 40mg/5mg, 40mg/10mg, and 80mg/5mg tablets are present in packing of 2 X 7’s

Misar AM 80mg/10mg is present in packing of 10’s

Misar H

BRAND NAME:

Misar H

GENERIC NAME:

Telmisartan+ Hydrochlorothiazide

DESCRIPTION:

Essential Hypertension patients on the prescription of a doctor. Patients whose BP is not adequately controlled with telmisartan 80 mg monotherapy may be switched to telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily, and finally titrated up to 160/25mg, if necessary. Patients whose BP is inadequately controlled by hydrochlorothiazide 25 mg once daily may be switched to telmisartan 80 mg/hydrochlorothiazide 12.5 once daily. Those patients controlled by hydrochlorothiazide 25 mg but who experience hypokalemia with this regimen may be switched to telmisartan 80 mg/hydrochlorothiazide 12.5 mg once daily.

COMPOSITION:

Telmisartan+ Hydrochlorothiazide

INDICATIONS:

Uncontrolled Hypertension

DOSAGE AND ADMINISTRATION:

Misar H 40mg/12.5mg and Misar H 80mg/12.5mg once daily 

CONTRAINDICATIONS:

Patients having Anuria, Hypersensitivity to sulfonamide-derived drugs, or any component of this product

PRESENTATION:

Misar H 40mg/12.5mg and 80mg/12.5mg tablets in blister pack of 2 x 7’s

Ferotox

Generic Name: Ferric Carboxymaltose

Racedo

DESCRIPTION:

Racecadotril is an enkephalinase inhibitor that inhibits the breakdown of endogenous opioids, thus reducing secretions.  

INDICATIONS:

It is indicated for the symptomatic treatment of acute diarrhoea in adults when causal treatment is not possible. If causal treatment is possible, it can be administered as a complementary treatment.

It is also indicated in infants (over 3 months old) and children as complementary symptomatic treatment of acute diarrhoea together with oral rehydration and the usual support measures, when these measures alone are insufficient to control the clinical condition, and when casual treatment is not possible.

DOSAGE AND ADMINISTRATION:

To initiate therapy in adults(one capsule containing 100mg of Racecadotril) is taken regardless of the time of day. After that, one capsule three times daily preferably before the meals, until diarrhea stops. Maximum duration of treatment is 7 days.

Treatment should be continued until two normal stools are recorded. Treatment should not exceed 7 days. Supportive therapies such as use of oral rehydration salts are encouraged. Racedo is also available in 10mg and 30mg sachets as granules for oral suspension and is intended for children less than 13 kg in weight and in 30mg sachets for children more than that.

The recommended dose is determined according to body weight: 1.5 mg/kg per dose (corresponding to 1 to 2 sachets), three times daily at regular intervals. For both adults and children, treatment should be continued until two normal stools are recorded. Treatment should not exceed 7 days. Long-term treatment with the drug is not recommended. 

Age

Sachets per administration

Children age from 3 to 9 months (weight less than 9kg approximately)1 sachet of 10mg per administration
Children age from 9 to 30 months (weight from 9 to 13kg approximately)2 sachets of 10mg per administration
Children age from 30 months to 9 years (weight from 13 to 27kg approximately)1 sachet of 30mg per administration
Children age over 9 years (weight more than 27kg approximately)2 sachets of 30mg per administration
Adults over 18 years1 capsule of 100mg per administration

Supportive therapies such as use of oral rehydration salts are encouraged.

Methods of Sachet Administration:

The powder is to be swallowed as it is.it can be added to food or to a glass of water or feeding bottle, mixing well and followed by immediate administration.

PRESENTATIONS:

Racedo 10mg Sachets: Pack of 1 X 16’s

Racedo 30mg Sachets: Pack of 1 X 10’s

Racedo 10mg Capsules: Alu. Alu. Blister pack of 1 X 10’s

Fosbu V

DESCRIPTION:

FOSBU V is a fixed-dose combination tablet containing sofosbuvir and velpatasvir for oral administration. Sofosbuvir is a nucleotide analog HCV NS5B polymerase inhibitor and velpatasvir is a NS5B inhibitor.

COMPOSITION:

FOSBU V 400mg/100mg Tablets. Each film coated tablet contains: Sofosbuvir …… 400mg Velpatasvir …… 100mg

INDICATIONS:

FOSBU V (sofosbuvir and velpatasvir) is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1,2,3,4,5, or 6 infection: without cirrhosis or with compensated cirrhosis and with decompensated cirrhosis for use in combination with ribavirin.

DOSAGE & ADMINISTRATION:

Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with FOSBU V (sofosbuvir and velpatasvir. The recommended dosage of FOSBU V (sofosbuvir and velpatasvir) is one tablet taken orally once daily with or without food. One tablet of FOSBU V (sofosbuvir and velpatasvir) contains 400mg of sofosbuir and 100 mg of velpatasvir. No dosage recommendation can be given for patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min) or with end stage renal disease (ESRD), due to higher exposures (up to 20-fold) of the predominant sofobuvir metabolite.

CONTRAINDICATIONS:

FOSBU V (sofosbuvir and velpatasvir) and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin.

UNDESIRABLE EFFECTS:

The reported adverse reactions are serious symptomatic bradycardia, headache, fatigue, asthenia, anemia, nausea, insomnia, irritability, diarrhea, rash, depression, decrease in hemoglobin, lipase elevation, creatinine, kinase elevation, increases in indirect bilirubin, skin rashes, sometimes with blisters, angioedema-like swelling angioedema, pruritis, chills, decreased appetite, pyrexia, and myalgia. If it is administered with ribavirin, refer to the prescribing information for ribavirin for a description of ribavirin-associated adverse reactions.

Patients should consult with their physician before taking any medicine.

DXL

DESCRIPTION:

DXL belongs to a class of Anti-ulcerant drugs and is a new Class of Proton Pump Inhibitor with a unique and exclusive DDR technology. It is the R-enantiomer of Lansoprazole, which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generation of PPIs (which includes Pantoprazole, Omeprazole, and Lansoprazole), Dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery release system. The active ingredient is released in two phases at different pH values and at different time points, resulting in two peak concentrations in the blood.

COMPOSITION:

Delayed-release Capsules 30mg and 60mg.

Each DXL 30mg capsule contains Dexlansoprazole 30 mg. 

Each DXL 60 mg capsule contains Dexlansoprazole 60mg.

INDICATIONS:

Dexlansoprazole is indicated for healing all grades of erosive esophagitis (EE), maintaining and healing of EE and relief of heartburn, and treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD).

DOSAGE AND ADMINISTRATION:

Healing of EE: 60 mg once daily for up to 8 weeks. Maintenance of healed EE: 30 mg once daily for up to 6 months. Symptomatic non-erosive GERD: 30 mg once daily for 4 weeks. Hepatic impairment: Consider 30 mg maximum daily dose for patients with moderate hepatic impairment. DXL can be taken without regard to food. DEXILANT should be swallowed whole. Alternatively, capsules can be opened, sprinkled on one tablespoon of applesauce, and swallowed immediately.

CONTRAINDICATIONS:

Patients with known hypersensitivity to any component of the formulation.

PRESENTATION:

DXL 30mg: Alu. Alu. Blister pack of 3 X 10’s capsules

DXL 60mg: Alu. Alu. Blister pack of 3 X 10’s capsules

Patients should consult with their physician before taking any medicine.

Evacef

DESCRIPTION

Evacef (Cefadroxil Monohydrate, USP) is a first generation cephalosporin antibiotic intended for oral administration.

INDICATIONS

Evacef (Cefadroxil) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

  1. Skin and Skin-Structure Infections caused by staphylococci and/or streptococci.
  2. Urinary Tract Infections caused by E. coli, P. mirabilis and Klebsiella species.        
  3. Pharyngitis and/or Tonsillitis caused Streptococcus pyogenes (Group A beta-hemolytic streptococci)
  4. Mild to moderate susceptible Gram positive Gram negative bacterial infections   

DOSAGE AND ADMINISTRATION

Adults

The recommended dosage of Evacef (Cefadroxil) is Urinary Tract Infections: For uncomplicated lower urinary tract infections (i.e., cystitis) the usual dosage is 1 or 2 gram per day in a single or divided doses. For all other urinary tract infections, the usual dosage is 2 gram per day in divided doses.

Skin and Skin Structure Infections: For skin and skin structure infections the usual dosage is 1 gram per day in single or divided doses.

Pharyngitis and Tonsillitis: Treatment of group A beta-hemolytic streptococcal pharyngitis and tonsillitis is 1 gram per day in single or divided doses for 10 days.

Mild to moderate susceptible Gram positive and Gram negative bacterial infections: The usual dose is 1 gram daily as single dose or in two divided doses.

Children

For urinary tract infections, the recommended daily dosage for children is 30 mg/kg/day in divided doses every 12 hours. For pharyngitis, tonsillitis, and impetigo, the recommended daily dosage for children is 30 mg/kg/day in a single dose or in equally divided doses every 12 hours; for other skin and skin structure infections, the recommended daily dosage is 30 mg/kg/day in equally divided doses every 12 hours. In the treatment of beta-hemolytic streptococcal infections, a therapeutic dosage should be administered for at least 10 days. In the treatment of mild to moderate susceptible Gram positive and Gram negative bacterial infections: the usual daily dose in 30 mg/kg 1n 2 divided doses.

See chart for total daily dosage for children

DAILY DOSE OF EVACEF SUSPENSION
CHILDS WEIGHT
125mg/5mL
250mg/5mL
10 Ibs4.5 Kg1 tsp
20 Ibs9.1 Kg2 tsp1 tsp
30 Ibs13.6 Kg3 tsp1 – 1.5 tsp
40 Ibs18.2 Kg4 tsp2 tsp
50 Ibs22.7 Kg5 tsp2 – 2.5 tsp
60 Ibs27.3 Kg6 tsp3 tsp

PRESENTATION

Evacef 500mg Capsules in pack of 2 X 6’s 

Evacef 125mg/5mL Suspension in pack of 60mL and 90mL bottle

Evacef 250mg/5mL Suspension in pack of 60mL and 90mL bottle

Maxum

DESCRIPTION:

Maxum (Cefepime) Injection is sterile, injectable product consisting of Cefepime Hydrochloride, a semi-synthetic, broad spectrum, cephalosporin antibiotic for parenteral administration.

  • Maxum 500mg Injection IM/IV
  • Maxum 1g Injection IM/IV
  • Maxum 2g Injection IV

INDICATIONS:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Maxum (Cefepime) Injection and other antibacterial drugs, Maxum Injection should be used only to teat or prevent infections that are proven to strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available they should be considered in selecting or modifying antibacterial therapy. It is used in the following conditions:

Pneumonia:

‘Maxum (Cefepime) Injection is indicated for pneumonia (moderate to severe) caused by Streptococcus pneumoniae, inducing cases associated with ‘concurrent bacteremia, Pseudomonas aeruginosa, Klebsiela pneumoniae, Enterobacter species.

Empiric Therapy for Febrile Neutropenic Patents:

Maxum (Cefepime) Injection as monotherapy indicated for empiric treatment of febrile neutropenic patents. In paints a high risk for severe infection including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate.

Uncomplicated and Complicated Urinary Tract Infections (Including pyelonephritis):

Maxum (Cefepime) Injection is indicated for uncomplicated and complicated urinary tract infections caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, inducing cases associated with concurrent bacteremia with these bacteria.

Uncomplicated Skin and kin Structure Infections:

Maxum (Cefepime) is indicated for uncomplicated skin and skin structure infections caused by staphylococcus aureus or Streptococcus pyogenes,

Complicated Intra-Abdominal Infections:

Maxum (Cefepime) Injection is indicated for complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli viridians group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.

DOSAGE AND ADMINISTRATION:

Adult and Pediatric Population:

The recommended adult and pediatric dosages and routes of administration are outlined below. Maxum (Cefepime) Injection should be administered intravenously over approximately 30 minutes. Recommended dosage Schedule for Cefepime Injection in patients with CrCL greater than 60 mL/min.

Site and Type of InfectionDoseFrequencyDuration (days)
Adults Moderate to Severe Pneumonia1-2g IVEvery 12 hours10
Empiric therapy for febrile neutropenic patients2 g IVEvery 8 hours7
Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis0.5-1 g IV / IMEvery 12 hours7-10
Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis2 g IVEvery 12 hours10
Moderate to Severe Uncomplicated Skin and Skin Structure Infections2 g IVEvery 12 hours10
Complicated Intra-abdominal Infections (used in combination with metronidazole)2 g IVEvery 12 hours7-10

Pediatric Patients (2 Months up to 16 Years):

The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is:

  • 50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).
  • For moderate to severe pneumonia due to P. aeruginosa give 50mg per kg per dose, every 8 hours.
  • 50 mg per kg per dose, every 8 hours for febrile neutropenic patients.

 Patients with Hepatic Impairment:

No adjustment is necessary for patients with hepatic impairment.

Patients with Renal Impairment:

In patients with creatinine clearance less than or equal to 60 mL/min, the dose of Maxum (Cefepime) Injection should be adjusted to compensate for the slower rate of renal elimination. The recommended initial dose of Maxum (Cefepime) Injection should be the same as in patients with CrCL greater than 60 mL/Min except in patients undergoing hemodialysis. The recommended doses of Maxum Injection in patients with renal impairment are: Recommended Dosing Schedule for Cefepime Injection in Adult Patients (Normal Renal Function, Renal Impairment, and Hemodialysis).

Creatinine Clearance (Ml/min)Recommended Maintenance Schedule
Greater than 60500 mg every 12 hours1 g every 12 hours2 g every 12 hours2 g every 8 hours
30-60500 mg every 24 hours1 g every 24 hours2 g every 24 hours2 g every 12 hours
11-29500 mg every 24 hours500 mg every 24 hours1 g every 24 hours2 g every 24 hours
Less than 11250 mg every 24 hours250 mg every 24 hours500 mg every 24 hours1 g every 24 hours
Continuous Ambulatory Peritoneal Dialysis (CAPD)500 mg every 48 hours1 g every 48 hours2 g every 48 hours2 g every 48 hours
Hemodialysis1 g on day 1500 mg every 24 hours1 g every 24 hours

In patients undergoing continuous ambulatory peritoneal dialysis, Maxum (Cefepime) Injection may be administered at normally recommended doses at a dosage interval of every 48 hours. The dosage of Maxum (Cefepime) Injection for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours. Maxum (Cefepime) Injection should be administered intravenously over approximately 30 minutes. Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of Maxum (Cefepime) Injection, it is desirable to discontinue the other solution. Solutions of cefepime, like those of most beta-lactam antibiotics, should not be added to solutions of ampicillin at a concentration greater than 40 mg per mL, and should not be added to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate or aminophylline because of potential interaction. However, if concurrent therapy with cefepime is indicated, each of these antibiotics can be administered separately.

PRESENTATION:

Maxum is supplied in following dosage forms, strengths and pack sizes:

Maxum 500mg InjectionIM/IV:

1 vial of 500mg Cefepime and 1 ampoule of 5mL of water for injection 

Maxum 1g Injection IM/IV:

1 vial of 1g Cefepime and 1 ampoule of 10mL of water for injection 

Maxum 1g Injection IV:

1 vial of 2g Cefepime and 1 ampoule of 10mL of water for injection 

Patients should consult with their physician before taking any medicine.

Fortez

DESCRIPTION:

Fortez contains Ceftazidime, a semisynthetic, third generation, broad-spectrum, beta-lactam antibacterial drug for parenteral administration. 

COMPOSITION:

Fortez 1g IM/IV Injection:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 1g

Ampoule: Water for injection 10mL

Fortez Injection 500mg IM/IV:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 500mg

Ampoule: Water for injection 5mL

Fortez Injection 250mg IM/IV:

Vial: Ceftazidime Pentahydrate equivalent to Ceftazidime 250mg

Ampoule: Water for injection 5mL

INDICATIONS:

Fortez (Ceftazidime) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:

1. Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Hemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).

2. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).

3. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

4. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant).

5. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.

6. Prophylaxis for transurethral resection of prostate

7. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Hemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).

8. Post-surgical Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

9. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole positive Proteus; Klebsiella spp.; and Escherichia coli.

10. Febrile neutropenia

11. Susceptible infections due to sensitive Gram-positive and Gram-negative bacteria, caused by pseudomonas species

It may be used alone in cases of confirmed or suspected sepsis. it may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient’s condition.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Fortez and other antibacterial drugs, Fortez should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

DOSAGE AND ADMINISTRATION:

Adult
Usual recommended dosage1 gram intravenous or intramuscularevery 8 to 12 hours
Uncomplicated urinary tract infection250 mg intravenous or intramuscularevery 12 hours
Bone and joint infections2 grams intravenousevery 12 hours
Complicated urinary tract infections500 mg intravenous or intramuscularevery 8 to 12 hours
Uncomplicated pneumonia; mild skin and skin-structure infections500 mg to 1 gram intravenous or intramuscularevery 8 hours
Serious gynecological and intra-abdominal infections2 grams intravenousevery 8 hours
Meningitis2 grams intravenousevery 8 hours
Very severe life-threatening infections, especially in immunocompromised patients2 grams intravenousevery 8 hours
Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function *30 to 50 mg/kg intravenous to a maximum of 6 grams per dayevery 8 hours
Neonates (0-4 weeks)30 mg/kg intravenousevery 12 hours
Infants and children (1 month – 12 years)30 to 50 mg/kg intravenous to a maximum of 6 grams per day tevery 8 hours

PRESENTATION:

Fortez 2g IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

Fortez 1g IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

Fortez 500mg IM/IV Injection: 

Vial containing powder and ampoule with 5mL water for injection

Fortez 250mg IM/IV Injection:

Vial containing powder and ampoule with 10mL water for injection

Xorbact

DESCRIPTION:

Sulbactam Sodium/Cefoperazone Sodium combination is available as a dry powder for reconstitution in 1:1 in terms of free SBT/CPZ. Sulbactam Sodium is a derivative of the basic penicillin nucleus. It is an irreversible beta-lactamase inhibitor for parenteral use only.

INDICATIONS: 

Monotherapy: 

Cefoperazone/Sulbactam is indicated for the treatment of the following infections when caused by susceptible organisms:

  • Respiratory tract infections (upper and lower)
  • Urinary tract infections (Upper and lower) 
  • Peritonitis, cholecystitis, cholangitis, and other Intra-abdominal infections
  • Septicemia
  • Meningitis
  • Skin and soft tissue infections
  • Bone and joint infections
  • Pelvic inflammatory disease, endometritis, gonorrhoea, and other infections of the genital tract 

Combination Therapy: 

Because of the broad-spectrum activity of cefoperazone/sulbactam, most infections can be treated adequately with this antibiotic alone. However, cefoperazonelsulbactam may be used concomitantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used, renal function should be monitored during the course of therapy.

DOSAGE AND ADMINISTRATION:

Daily dosage recommendations for sulbactam/cefoperazone in adults are as follows:

Ratio

SBT/CPZ (g)

Sulbactam Activaity (g)

Cefoperazone Activity (g)

1:1

2.0 _ 4.0

1.0 _ 2.0

1.0 _ 2.0

 

Doses should be administered every 12 hours in equally divided doses. In severe or refractory infections, the daily dosage of cefoperazone/sulbactam may be increased up to 8g of the 1:1 ratio (i.e. 4g Cefoperazone activity), patients receiving the 1:1 ratio may require additional cefoperazone administered separately. Doses should be administered every 12 hours in equally divided doses. The recommended maximum daily dosage of sulbactam is 4g.

CONTRAINDICATIONS: 

Cefoperazone/sulbactam is contraindicated in patients with known allergy to penicillin, sulbactam, cefoperazone, or any of the cephalosporins.

RESENTATION:

Xorbact is supplied in the following dosage forms, strengths and pack sizes: 

Xorbact 500mg IM/IV Injection: 

1 vial of 250mg Cefoperazone + 250mg Sulbactam and 1 ampoule of 5mLwater for injection. 

Xorbact 1g IM/IV Injection: 

1 vial of 500mg Cefoperazone + 500mg Sulbactam and 1 ampoule of 5mL water for injection. 

Xorbact 2g IM/IV Injection:

1 vial of 1g Cefoperazone + 1g Sulbactam and 1 ampoule of 10mL water for injection.

Patients should consult with their physician before taking any medicine.

Cefia

DESCRIPTION:

Cefixime (Capsules/Suspension) is a semi-synthetic, Cephalosporin antibiotic for oral administration.

INDICATIONS:

  • Acute Exacerbations of Chronic Bronchitis (caused by Streptococcus pneumoniae and Hemophilus influenzae)
  • Community-acquired Pneumonia
  • Uncomplicated urinary tract infections (caused by Escherichia coli and Proteus mirabilis)
  • Pyelonephritis
  • In the treatment of otitis media (caused by Hemophilus influenzae, Moraxella catarrhalis, and Streptococcus pyogenes), sinusitis, pharyngitis & tonsillitis (caused by Streptococcus pyogenes)
  • Uncomplicated gonorrhea (cervical, urethral) caused by Neisseria gonorrhoeae (penicillinase-and non-penicillinase-producing isolates)

The use of cefixime should be reserved for infections where the causative Organism is known or suspected to be resistant to other commonly used antibiotics or where treatment failure may carry significant risk.

DOSAGE AND ADMINISTRATION:

The usual course of treatment is 7 days. In severe cases this can be extended to 14 days.

Adults and Children Over 10 Years of Age (Body Weight Is Greater than 50 Kg):

The recommended dose is 400 mg daily according to the severity of the infection, given either as a 400 mg single dose or as 200 mg in two divided doses.

Elderly Patients:

Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed, and dosage should be adjusted in severe impairment.

Children Younger Than 10 Years Of Age (Body Weight Is Lower Than 50 KG) – Pediatric Oral Suspension:

The recommended dosage for children is 8 mg/kg/day administered as a single dose or in two divided doses. The following table describes a range of periodic doses according to the weight of the child.

Children weighing more than 50 kg or older than 10 years should be treated with the recommended adult dose (200-400 mg daily), depending on the severity of the infection.

Child’s weight
Daily Dose
Daily dose according to the dispenser graduations
5 kg
40 mg2 mL (once daily) or 1 mL (twice daily)
10 kg
80 mg4 mL (once daily) or 2 mL (twice daily)
12.5 kg
100 mg5 mL (once daily) or 2.5 mL (twice daily)
15 kg
120 mg6 mL (once daily) or 3 mL (twice daily)
17.5 kg
140 mg7 mL (once daily) or 3.5 mL (twice daily)
20 kg
160 mg8 mL (once daily) or 4 mL (twice daily)
22.5 kg
180 mg9 mL (once daily) or 4.5 mL (twice daily)
25 kg
200 mg10 mL (once daily) or 5 mL (twice daily)

PRESENTATIONS:

Cefia 200mg Capsules in packs of 2 X 5’s

Cefia 400mg Capsules in packs of 1 X 5’s

Cefia 100mg/5mL Suspension in pack of 30mL and 60mL bottle

Cefia DS 200mg/5mL Suspension in pack of 30mL bottle

Patients should consult with their physician before taking any medicine.

Ceftro

DESCRIPTION:

Ceftriaxone is a semi synthetic 3rd generation cephalosporin antibiotic, with high degree of stability of B-Lactamase, broad spectrum activity and effectiveness and convenience of long action

DOSAGE AND ADMINISTRATION:

Ceftriaxone may be administered intravenously or intramuscularly. Ceftriaxone for injection should be administered intravenously by infusion over a period of 30 minutes.

Adults:

The usual adult daily dose is 1 to 2 grams given once a day (or in equally divided doses twice a day) depending on the type and severity of infection. For infections caused by Staphylococcus aureus (MSSA), the recommended daily dose is 2 to 4 grams, in order to achieve >90% target attainment. The total daily dose should not exceed 4 grams. If Chlamydia trachomatis is a suspected pathogen, appropriate antichlamydial coverage should be added, because ceftriaxone sodium has no activity against this organism. For preoperative use (surgical prophylaxis), a single dose of 1 gram administered intravenously 1/2 to 2 hours before surgery is recommended. Generally, ceftriaxone therapy should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4 to 14 days; in complicated infections, longer therapy may be required. When treating infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days. No dosage adjustment is necessary for patients with impairment of renal or hepatic function. Pediatric Patients: For the treatment of skin and skin structure infections, the recommended total daily dose is 50 to 75 mg/kg given once a day (or in equally divided doses twice a day). The total daily dose should not exceed 2 grams. For the treatment of serious miscellaneous infections other than meningitis, the recommended total daily dose is 50 to 75 mg/kg, given in divided doses every 12 hours. The total daily dose should not exceed 2 grams. In the treatment of meningitis, it is recommended that the initial therapeutic dose be 100 mg/kg (not to exceed 4 grams). Thereafter, a total daily dose of 100 mg/kg/day (not to exceed 4 grams daily) is recommended. The daily dose may be administered once a day (or in equally divided doses every 12 hours). The usual duration of therapy is 7 to 14 days. 

Neonates: Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone for injection. Ceftriaxone is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium.

PRESENTATION:

Ceftro is supplied in following dosage forms, strengths and pack sizes.

Ceftro 250mg IM Injection:

1 vial of 250mg Ceftriaxone and 1 ampoule of 2mL lignocaine hydrochloride 1%

Ceftro 500mg IM Injection: 

1 vial of 500mg Ceftriaxone and 1 ampoule of 2mL lignocaine hydrochloride 1%

Ceftro 250mg IV Injection: 

1 vial of 250mg Ceftriaxone and 1 ampoule of 5mL water for injection

Ceftro 500mg IV Injection:

1 vial of 500mg Ceftriaxone and 1 ampoule of 5mL water for injection

Ceftro 1g IV Injection: 

1 vial of 1g Ceftriaxone and 1 ampoule of 10mL water for injection

Ceftro 2g IV Injection: 

1 vial of 2g Ceftriaxone and 1 ampoule of 10mL water for injection

Tiovair-F

DESCRIPTION:

It is a synthetic, non-chiral, quaternary ammonium compound. It is sparingly soluble in water and soluble in methanol. The dry powder formulation within the Tiovair capsule is intended for oral inhalation only. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors.

COMPOSITION:

Tiovair Rotacaps: Each capsule contains: Tiotropium (as Bromide Monohydrate) 18 mcg

INDICATIONS:

Tiovair is indicated as a long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.

DOSAGE & ADMINISTRATION:

For oral Inhalation only Inhalation of the powder contents of a single TIOVAIR capsule (18 mcg) once daily CONTRAINDICATIONS Hypersensitivity to tiotropium, ipratropium or any components of Tiovair capsules

CONTRAINDICATIONS:

Tiotropium bromide inhalation powder is contraindicated in patients with hypersensitivity to tiotropium, atropine or its derivatives, e.g. ipratropium or oxitropium or to the excipient lactose monohydrate.

PRESENTATION:

Available as dry powder inhalation capsules. Tiovair: Tiotropium 18 mcg Each sale pack contains 20 dry powder inhalation capsules.

Patients should consult with their physician before taking any medicine.

Lipirex

BRAND NAME:

Lipirex

GENERIC NAME:

Atorvastatin

DESCRIPTION:

Patients with elevated LDL-cholesterol, apolipoprotein B, and triglycerides, and to increase HDL cholesterol

COMPOSITION: 

Atorvastatin Calcium

INDICATIONS:

Elevated LDL-cholesterol, apolipoprotein B, and triglycerides

DOSAGE AND ADMINISTRATION:

10mg, 20mg or 40mg may be given once daily at any time of the day with or without food

CONTRAINDICATIONS:

Hypersensitive to this medication, have active liver diseases, or have unexplained persistent elevations of serum transaminases exceeding three times the upper limit of normal, pregnant, breastfeeding.

PRESENTATION:

Lipirex 10mg, 20mg, and 40mg in blister pack of 10’s

Loprin

BRAND NAME:

Loprin 

GENERIC NAME:

Enteric-coated Aspirin

DESCRIPTION:

Loprin (Enteric-coated Aspirin) is a prescription medicine used to: ISH (Ischemic Heart Disease) and stroke

PRECAUTIONS:

Before taking Loprin Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Inhibition of platelet aggregation in order to reduce the risk of IHD (ischemic heart disease) in patients who have had a previous history of IHD and to reduce risk of recurrent transient ischemic attacks or stroke in the patient who have had transient ischemia of the brain due to fibrin platelet emboli. Aspirin is also indicated to reduce the risk of graft occlusion following aortic coronary by-pass surgery.

DOSAGE AND ADMINISTRATION:

One tablet of Loprin (Enteric-coated Aspirin) 75mg or one tablet of Loprin (Enteric-coated Aspirin) 150mg per day or as directed by the doctor, preferably at the same time each day.

CONTRAINDICATIONS:

Should not be administered to patient with hemorrhagic disorders, with gout, or those with intolerance to aspirin. Use with caution in patient with impaired renal or hepatic function. Aspirin should not be taken by patient having hypoprothrombinemia, hemopohilia, and active peptic ulceration.

UNDESIRABLE EFFECTS:

Salicylates should be used with caution in patients with history of peptic ulceration or coagulation abnormalities. They may also induce gastrointestinal hemorrhage, occasionally major. In large doses salicylates may also decrease insulin requirements.

PRESENTATION:

Loprin 75mg and 150mg enteric-coated tablets blister pack of 30 tablets

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Misar

BRAND NAME:

Misar

GENERIC NAME:

Telmisartan

DESCRIPTION: 

Misar (Telmisartan) tablets are for once-daily oral administration and should be taken with liquid, with or without food. Precautions are to be taken before handling or administering the medicinal product. Misar (Telmisartan) should be kept in the sealed blister due to the hygroscopic property of the tablets. Tablets should be taken out of the blister shortly before administration. 

COMPOSITION:

Telmisartan

INDICATIONS:

Hypertension

DOSAGE AND ADMINISTRATION:

Misar (Telmisartan) tablets are for once-daily oral administration

CONTRAINDICATIONS:

Hypersensitivity to Telmisartan, Second and third trimesters of pregnancy, Cholestasis, Biliary obstructive disorders Severe hepatic impairment. Special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.

PRESENTATION:

Misar 20mg, 40mg, and 80mg tablets in blister pack of 2 x 7’s

Triforge

BRAND NAME:

Triforge

GENERIC NAME:

Amlodipine + Valsartan + Hydrochlorothiazide

DESCRIPTION:

 Triforge (Amlodipine +Valsartan + Hydrochlorothiazide) is a prescription medicine used to: Hypertension

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. If you are patient with diabetes and using Alikserin. If you are pregnant and breastfeeding discuss with doctor. If you have liver or heart problem then Triforge is to be taken with caution

DOSAGE AND ADMINISTRATION:

  • Take Triforge exactly as your doctor tells you, Take Triforge once daily, Triforge can be taken with or without food
  • Triforge (Amlodipine, Valsartan & Hydrochlorothiazide) 

INDICATIONS:

Hypertensive patients on prescription of a doctor

CONTRAINDICATIONS:

Do not use in patients with known hypersensitivity to any component. Do not co-administer aliskiren with Triforge (amlodipine and valsartan) in patients with diabetes.

ADVERSE EVENTS:

The major adverse reactions include peripheral edema, nasopharyngitis, upper respiratory tract infection and dizziness. Hypokalemia may develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy. Dilutional hyponatremia may occur in edematous patients in hot weather; appropriate therapy is water restriction.

PRESENTATION: Triforge is presented in 5mg/160mg/12.5mg, 5mg/160mg/25mg, 10mg/160mg/12.5mg, 10mg/160mg/25mg, and 10mg/320mg/25mg film-coated tablets

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Blokium

DESCRIPTION:

Atenolol is a beta-adrenergic blocking drug which acts preferentially on Beta Receptors in the heart.

COMPOSITION:

Blokium 100 contains Atenolol 100 mg. Blokium 50 contains Atenolol 50 mg Blokium 25 contains Atenolol 25 mg. Blokium DIU 100 contains Atenolol 100 mg and Chlorthalidone 25 mg. Blokium DIU 50 contains Atenolol 50 mg and Chlorthalidone 12.5 mg.

INDICATIONS:

Blokium; Angina Pectoris, management of all types of hypertension including hypertension of renal origin. Blokium DIU; Treatment of hypertension.

DOSAGE & ADMINISTRATION:

Blokium; 50-100 mg once a day. However, dosage must be adjusted according to the response. BLOKIUM DIU; 1 tablet daily.

CONTRAINDICATIONS:

Treatment with Blokium & Blokium DIU is contraindicated in cases of heart block (second or third degree). The drug must not be used in patients with untreated cardiac failure.

PRESENTATION:

Available in five strengths in following pack sizes. Blokium 100mg: Blister Pack of 2×10. Blokium 50mg: Blister Pack of 3×10. Blokium 25mg: Blister Pack of 3X10. Blokium DIU 100: Blister pack of 2×10. Blokium DIU 50: Blister pack of 2×10.

PREGNANCY & LACTATION:

Drug should be avoided in Pregnancy, unless strictly necessary.

Patients should consult with their physician before taking any medicine.

Nebix

BRAND NAME:

Nebix

GENERIC NAME:

Nebivolol

DESCRIPTION: 

Nebix is a prescription medicine used to treat Hypertension & Chronic Heart Failure

COMPOSITION:

Nebivolol

INDICATIONS:

Hypertension and Chronic Heart Failure

DOSAGE AND ADMINISTRATION:

Take Nebix (Nebivolol) with or without meals. Swallow Nebivolol tablets as a whole; do not crush, break or chew. The maximum recommended daily dose of Nebivolol is 10mg once daily. If a dose of Nebivolol is missed, take the prescribed dose at the next scheduled time; do not double the next dose. 

CONTRAINDICATIONS:

Nebix is contraindicated in patients with severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), or severe hepatic impairment (Child-Pugh >B), and in patients who are hypersensitive to any component of this product.

PRESENTATION:

Nebix 2.5mg, 5mg, and 10mg film-coated tablets in blister pack of 1 x 14’s

Ranola

BRAND NAME:

Ranola

GENERIC NAME:

Ranolazine

DESCRIPTION:

Chronic stable angina patients on the prescription of a doctor, take Ranola (Ranolazine) with or without meals. Swallow Ranolazine tablets as a whole; do not crush, break or chew. The maximum recommended daily dose of Ranolazine is 1000mg twice daily. If a dose of Ranolazine is missed, take the prescribed dose at the next scheduled time; do not double the next dose. 

COMPOSITION:

Ranolazine

INDICATIONS:

Chronic stable angina

DOSAGE AND ADMINISTRATION:

Oral administration of 500mg twice daily or 1000mg twice daily 

CONTRAINDICATIONS:

Take Ranola (Ranolazine) with or without meals. Swallow Ranolazine tablets as a whole; do not crush, break or chew. The maximum recommended daily dose of Ranolazine is 1000mg twice daily. If a dose of Ranolazine is missed, take the prescribed dose at the next scheduled time; do not double the next dose. 

PRESENTATION:

Ranola 500mg and 1000mg tablets in blister pack of 2 x 7’s

Biforge

BRAND NAME:

Biforge

GENERIC NAME:

Amlodipine + Valsartan

DESCRIPTION:

Biforge is a prescription medicine used to: Hypertension

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. If you are patient with diabetes and using Alikserin. If you are pregnant and breastfeeding discuss with doctor

DOSAGE AND ADMINISTRATION:

Take Biforge exactly as your doctor tells you Take Biforge once each day. Biforge can be taken with or without food. 

CONTRAINDICATIONS:

Hypertensive patients on prescription of a doctor

CONTRAINDICATIONS:

Do not use in patients with known hypersensitivity to any component. Do not co-administer aliskiren with Biforge (Amlodipine + Valsartan) in patients with diabetes.

ADVERSE EVENTS:

The major adverse reactions include peripheral edema, nasopharyngitis, upper respiratory tract infection and dizziness

PRESENTED:

Biforge is presented in 5mg/180mg, 5mg/160mg or 10mg/160mg film-coated tablets  

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Pidogrel

BRAND NAME:

Pidogrel and Pidogrel-AP

GENERIC NAME:

Clopidogrel & Clopidogrel + Aspirin

DESCRIPTION: 

Clopidogrel & Clopidogrel + Aspirin are inhibitors of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

COMPOSITION: 

Clopidogrel & Clopidogrel + Aspirin

INDICATIONS:

Pidogrel is a P2Y12 platelet inhibitor indicated for Acute coronary syndrome and recent myocardial infarction

DOSAGE AND ADMINISTRATION:

Pidogrel 75mg,  Pidogrel-AP 75mg (75mg/75mg) & Pidogrel-AP 150mg (75mg/150mg) once daily

CONTRAINDICATIONS:

Active pathological bleeding, such as a peptic ulcer or intracranial hemorrhage

Hypersensitivity to clopidogrel or any component of the product

PRESENTATION:

Pidogrel 1 x 10`s, Pidogrel-AP 75mg (75mg/75mg) and Pidogrel-AP 150mg (75mg/150mg) 1 x 10`s

Rosulin

BRAND NAME:

Rosulin

GENERIC NAME:

Rosuvastatin

DESCRIPTION:

Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol.

COMPOSITION:

Rosuvastatin calcium

INDICIATIONS:

Rosulin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, non-HDL-C, ApoB, and triglycerides levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. 

DOSAGE AND ADMINISTRATION:

Rosulin 5mg, 10mg, and 20mg once daily  

CONTRAINDICATIONS:

Rosuvastatin is contraindicated in patients allergic to any component of the product. In patients with active liver disease.

PRESENTATION:

Rosulin 5mg, 10mg, and 20mg tablets in Alu-Alu blister pack of 10’s

Epliron

BRAND NAME:

Epliron

GENERIC NAME:

Eplerenone

DESCRIPTION:

Patients with Congestive Heart Failure Post-Myocardial Infarction

Hypertension may take once daily as per prescribed by the doctor

COMPOSITION:

Eplerenone

INDICATIONS:

Congestive Heart Failure, Post-Myocardial Infarction, Hypertension

DOSAGE AND ADMINISTRATION:

Congestive Heart Failure: 25mg once daily and titrated to the recommended dose of 50mg once daily

Hypertension: 50mg once daily and may be titrated to the recommended dose of 50mg twice daily

CONTRAINDICATIONS:

For all patients: Serum potassium >5.5 mEq/L at initiation, Creatinine clearance ≤30 mL/min, 

Concomitant use with strong CYP3A4 inhibitors 

For the treatment of hypertension: Type 2 diabetes with microalbuminuria, 

Serum creatinine >2.0 mg/dL in males, >1.8 mg/dL in females, Creatinine clearance 

PRESENTATION:

Epliron 25mg and 50mg tablets in blister pack of 14’s

Sacuvia

BRAND NAME:

Sacuvia

GENERIC NAME:

Sacubitril + Valsartan

DESCRIPTION: 

Sacuvia is a prescription medicine used to treat heart failure.

COMPOSITION: 

Sacubitril + Valsartan

INDICATIONS:

Heart failure patients on the prescription of a doctor

DOSAGE AND ADMINISTRATION:

Take Sacuvia 2 times each day. Your doctor may change your dose of Sacuvia during treatment. If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time.

CONTRAINDICATIONS:

Sacuvia is contraindicated in patients with hypersensitivity to any component. Patients with a history of angioedema related to previous ACE inhibitor or ARB therapy and with concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor or with concomitant use of aliskiren in patients with diabetes.

PRESENTATION:

Sacuvia 50mg, 100mg, and 200mg film-coated tablets in blister pack of 1 x 14’s 

Ivaset

BRAND NAME:

Ivaset

GENERIC NAME:

Ivabradine

DESCRIPTION: 

Ivaset is a prescription medicine used to treat heart failure.

COMPOSITION:

Ivabradine

INDICATIONS:

Heart failure

DOSAGE AND ADMINISTRATION:

Take Ivaset 2 times each day. Your doctor may change your dose of Ivaset during treatment. If you miss a dose, take it as soon as you remember. If it is close to your next dose, do not take the missed dose. Take the next dose at your regular time.

CONTRAINDICATIONS:

Do not take Ivaset if your blood pressure is less than 90/50 mmHg, your resting heart rate is less than 60 bpm prior to treatment, severe hepatic impairment, or are allergic to Ivabradine or any of the ingredients in Ivaset

PRESENTATION:

Ivaset 5mg and 7.5mg film-coated tablets in blister pack of 2×7’s

Rivaro

BRAND NAME:

Rivaro

GENERIC NAME:

Rivaroxaban

DESCRIPTION:

A selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaro inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

COMPOSITION: 

Rivaroxaban

INDICATIONS:

Nonvalvular Atrial Fibrillation, Treatment of DVT and/or PE, Reduction in the Risk of Recurrence of DVT and/or PE, Prophylaxis of DVT Following Hip or Knee Replacement Surgery, Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications, CAD or PAD

DOSAGE AND ADMINISTRATION:

Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food.

Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment. 

Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment. 

Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily with or without food. Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding: 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days.

CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75-100 mg) once daily.

CONTRAINDICATIONS:

If you are 75 years of age or older. if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking rivaroxaban. Your doctor may tell you to stop taking rivaroxaban before the surgery or procedure

PRESENTATION:

Rivaro 2.5mg tablets in pack of 2 x 14`s

Rivaro 10mg tablets in pack of 1 x 10`s

Rivaro 15mg and 20mg tablets in pack of 2 x 14`s

Valforge

DESCRIPTION:

Valsartan is an angiotensin II receptor antagonist with actions similar to those of losartan.

COMPOSITION:

Valforge 40mg Tablets: Each film coated tablet contains: Valsartan U.S.P. …………. 40 mg. Valforge 80mg Tablets Each film coated tablet contains: Valsartan U.S.P. …………. 80 mg. Valforge 160mg Tablets Each film coated tablet contains: Valsartan U.S.P. ……….. 160 mg.

INDICATIONS:

Hypertension Valforge (Valsartan) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Valforge (Valsartan) may be used alone or in combination with other antihypertensive agents. Heart Failure Valforge (Valsartan) is indicated for the treatment of heart failure (NYHAclass II-IV). Post – Myocardial Infarction Valforge (Valsartan) is indicated to reduce cardiovascular mortality, in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.

DOSAGE & ADMINISTRATION:

Adult Hypertension The recommended starting dose of Valforge (Valsartan) is 80 mg or 160 mg once daily when used as mono therapy in patients who are not volume-depleted. Patients requiring greater reductions may be started at the higher dose. Valforge (Valsartan) may be used over a dose range of 80 mg to 320 mg daily, administered once a day. The antihypertensive effect is substantially present within 2 weeks and maximal reduction is generally attained after 4 weeks. If additional antihypertensive effect is required over the starting dose range, the dose may be increased to a maximum of 320 mg or a diuretic may be added. Addition of a diuretic has a greater effect than dose increases beyond 80 mg. No initial dosage adjustment is required for elderly patients, for patients with mild or moderate renal impairment, or for patients with mild or moderate liver insufficiency. Care should be exercised with dosing of Valforge in patients with hepatic or severe renal impairment. It may be administered with other antihypertensive agents. It may be administered with or without food. Pediatric Hypertension 6 to 16 Years of Age For children who can swallow tablets, the usual recommended starting dose is 1.3 mg/kg once daily (up to 40 mg total). The dosage should be adjusted according to blood pressure response. Doses higher than 2.7 mg/kg (up to 160 mg) once daily have not been studied in pediatric patients 6 to 16 years old. No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate <30 mL/min/1.73 m2. It is not recommended for patients <6 years old. Heart Failure The recommended starting dose of Valforge (Valsartan) is 40 mg twice daily. Up titration to 80 mg and 160 mg twice daily should be done to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses. Post-Myocardial Infarction Valforge (Valsartan) may be initiated as early as 12 hours after a myocardial infarction. The recommended starting dose of Valforge (Valsartan) is 20 mg twice daily. Patients may be up titrated within 7 days to 40 mg twice daily, with subsequent titrations to a target maintenance dose of 160 mg twice daily, as tolerated by the patient. If symptomatic hypotension or renal dysfunction occurs, consideration should be given to a dosage reduction. It may be given with other standard post-myocardial infarction treatment, including thrombolytics, aspirin, beta-blockers, and statins.

CONTRAINDICATIONS:

  • Do not use in patients with known hypersensitivity to any component.
  • Do not co-administer aliskiren with Valforge (Valsartan) in patients with diabetes.

PRESENTATION:

1. Valforge 40mg Tablets: Alu. Alu. blister pack of 2×7’s. 2. Valforge 80mg Tablets: Alu. Alu. blister pack of 2×7’s. 3. Valforge 160mg Tablets: Alu. Alu. blister pack of 2×7’s

Patients should consult with their physician before taking any medicine.

Herbesser

Brand Name:

HERBESSER (tablets), HERBESSER SR (capsules)

Generic Name:

Diltiazem

Description: 

HERBESSER is a prescription medicine used to treat Hypertension & Angina

Composition: 

Diltiazem hydrochloride

Indications:

Herbesser is a prescription medicine used to treat the symptoms of chest pain (angina), high blood pressure (hypertension), as well as certain heart rhythm disorders. Herbesser may be used alone or with other medications.

Dosage & Administration:

Dosage must be adjusted to each patient’s needs. For angina, starting with 30 mg twice daily, before meal and at bedtime, dosage should be increased gradually to 60 mg twice daily.  For hypertension, the optimum dosage range appears to be 90 – 180 mg twice daily.

Contraindications:

HERBESSER is contraindicated in patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, patients with second- or third-degree AV block, patients with severe hypotension (less than 90 mm Hg systolic), or patients who have demonstrated hypersensitivity to the drug, and patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

Presentation:

Herbesser 30 mg & Herbesser 60 mg tablets ( 30’s)

Herbesser 90 SR & Herbesser 180 SR capsules (10’s)

Tagipmet

BRAND NAME:

Tagipmet

GENERIC NAME:

Sitagliptin + Metformin

DESCRIPTION:

Tagipmet (Sitagliptin + Metformin) is a prescription medicine used to treat: Diabetes Mellitus Type-2

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients, or had any previous episode of ketoacidosis.

DOSAGE AND ADMINISTRATION:

The dosage of Tagipmet should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100mg sitagliptin and 2000mg metformin.

INDICATIONS:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

Contraindicated in  patients with: Renal impairment or renal dysfunction (e.g., serum creatinine levels greater than or equal to 1.5mg/dL for men, greater than or equal to 1.4mg/dL for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute septicemia. History of a serious hypersensitivity reaction to Tagipmet (or any of its components), such as anaphylaxis or angioedema.

ADVERSE EVENTS:

The reported adverse effects with Sitagliptin include headache, dizziness and gastrointestinal disturbances. 

PRESENTATIONS:

Tagipmet is presented in 50mg/500mg and 50mg/1000mg tablets

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Tagip

BRAND NAME:

Tagip

GENERIC NAME:

Sitagliptin

DESCRIPTION:

Tagip (Sitagliptin) is a prescription medicine used to treat Diabetes Mellitus Type-2

PRECAUTIONS:

Tell your doctor if you have hypersensitivity to the active substance or to any of the excipients. Or had any previous episode of ketoacidosis.

DOSAGE AND ADMINISTRATION:

The recommended dose of Tagip is 100mg once daily. Sitagliptin can be taken with or without food 100mg once daily for patients with mild renal impairment (creatinine clearance 50ml/min or more); no adjustment is necessary. 50mg once daily patients with moderate renal impairment (creatinine clearance less than 50mL/min). 25mg once daily in patients with severe renal impairment (creatinine clearance less than 30mL/min); or end stage renal disease requiring hemodialysis or peritoneal dialysis

INDICATION:

Diabetes Type-2 patients on prescription of a doctor

CONTRAINDICATIONS:

Tagip is contraindicated in patients with; Hypersensitivity to the active substance or to any of the excipients. Type 1 diabetes mellitus or for the treatment of ketoacidosis.

ADVERSE EVENTS:

The reported adverse effects with Sitagliptin include headache, dizziness and gastrointestinal disturbances. 

PRESENTATION: 

Tagip is presented in 25mg, 50mg, and 100mg tablets

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Daploz

BRAND NAME:

Daploz 

GENERIC NAME:

Dapagliflozin

DESCRIPTION:

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose resorption in the proximal tubule of the nephron and causing glycosuria.

COMPOSITION:

Each film coated tablet contains: Daploz 5 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate) 5 mg. Daploz 10 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate) 10 mg. Daplozmet 5/850 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate) 5 mg. Metformin Hydrochloride B.P.850 mg. Daplozmet 5/1000 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate)5 mg. Metformin Hydrochloride B.P.1000 mg.

INDICATIONS:

Daploz/Daplozmet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors Daploz/Daplozmet is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

DOSAGE & ADMINISTRATION:

To improve glycemic control in patients with T2D, the recommended starting dose of Daploz is 5 mg once daily, taken in the morning. In patients tolerating Daploz 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. To reduce the risk of hospitalization for heart failure in patients with T2D, the recommended dose of Daploz is 10 mg once daily

CONTRAINDICATIONS:

Prior serious hypersensitivity reaction to Daploz Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis

PRESENTATION:

Daploz 5 mg tablets: Alu. Alu. blister pack of 2 x 7’s. Daploz 10 mg tablets: Alu. Alu. blister pack of 2 x 7’s. Daplozmet 5/850 mg tablets: Alu. Alu. blister pack of 2 x 7’s. Daplozmet 5/1000 mg tablets: Alu. Alu. blister pack of 2 x 7’s.

Patients should consult with their physician before taking any medicine.

Daplozmet

DESCRIPTION:

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose resorption in the proximal tubule of the nephron and causing glycosuria.

COMPOSITION:

Daplozmet 5/850 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate) 5 mg. Metformin Hydrochloride B.P.850 mg. Daplozmet 5/1000 mg tablet: Dapagliflozin (as dapagliflozin propanediol monohydrate)5 mg. Metformin Hydrochloride B.P.1000 mg.

INDICATIONS:

Daploz/Daplozmet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and established cardiovascular disease or multiple cardiovascular risk factors Daploz/Daplozmet is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

DOSAGE & ADMINISTRATION:

To improve glycemic control in patients with T2D, the recommended starting dose of Daploz is 5 mg once daily, taken in the morning. In patients tolerating Daploz 5 mg once daily who require additional glycemic control, the dose can be increased to 10 mg once daily. To reduce the risk of hospitalization for heart failure in patients with T2D, the recommended dose of Daploz is 10 mg once daily

CONTRAINDICATIONS:

Prior serious hypersensitivity reaction to Daploz Severe renal impairment (eGFR <30 mL/min/1.73 m2), end-stage renal disease, or patients on dialysis

PRESENTATION:

Daplozmet 5/850 mg tablets: Alu. Alu. blister pack of 2 x 7’s. Daplozmet 5/1000 mg tablets: Alu. Alu. blister pack of 2 x 7’s.

STOGARE:

Do not store above 30°C,keep in dry place, protect from light

Xormet

DESCRIPTION:

XORMET XR (Metformin HCl Extended Release) is an oral anti-diabetic medicine that belongs to the group of biguanides.

Metformin, the active ingredient in XORMET XR, reduces hepatic glucose production, increases insulin sensitivity in muscles and delays intestinal glucose absorption.

COMPOSITION:

XORMET XR 500mg: Each extended release tablet contains Metformin HCI B.P. 500mg. XORMET XR 1000mg: Each extended release tablet contains Metformin HCI B.P. 1000mg.

INDICATIONS:

XORMET XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

DOSAGE & ADMINISTRATION:

XORMET XR should be taken once daily with the evening meal. The dosage of XORMET XR must be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended daily dose of 2000 mg. The starting dose of XORMET XR in patients who are not currently taking metformin is 500 mg once daily, with the evening meal. The dose can be up titrated in 500 mg increments no sooner than every 1-2 weeks if a higher dose of XORMET XR is needed and there are no gastrointestinal adverse reactions. If XORMET XR is considered appropriate for a patient already receiving immediate-release metformin, the patient can be switched to XORMET XR once daily at the same total daily dose, up to 2000 mg once daily. XORMET XR tablets must be swallowed whole and never split, crushed or chewed. If a dose of XORMET XR is missed, patients should be cautioned against taking two doses of 2000 mg the same day. Resume dosing as according to prescribing recommendations. Co-administration of XORMET XR with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia.

CONTRAINDICATIONS:

METFORMIN is contraindicated in patients with: • Renal impairment (e.g., serum creatinine levels ≥ 1.5 mg/dl for men, ≥ 1.4 mg/dl for women or abnormal creatinine clearance), which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia. Known hypersensitivity to metformin hydrochloride. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. Diabetic ketoacidosis should be treated with insulin.

UNDESIRABLE EFFECTS:

The reported adverse effects of metformin are Diarrhea, nausea, vomiting, flatulence, asthenia, indigestion, abdominal discomfort (abdominal pain & abdominal distention), headache, abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation, constipation, dyspepsia, heart burn, dizziness & upper respiratory tract infection. Patient may have taste disturbances, there may be a weight loss. Skin reactions have been reported rarely. Hypoglycemia is rare with biguanide given alone, although it may occur if other contributing factors or drugs are present.

PRESENTATION:

XORMET XR 500mg tablets: Blister pack of 5 x 10’s tablet. XORMET XR 1000mg tablets: Blister pack of 5 x 10’s tablet.

PREGNANCY & LACTATION:

Lactic acidosis can occur due to metformin accumulation. The risk increases with conditions such as sepsis, dehydration, excess alcohol intake, hepatic insufficiency, renal impairment, and acute congestive heart failure. The symptoms include malaise, myalgia’s, respiratory distress, increasing somnolence, and nonspecific abdominal distress. Laboratory abnormalities include low pH, increased anion gap and elevated blood lactate. If acidosis is suspected, discontinue XORMET XR and hospitalize the patient immediately. · Conditions associated with hypoxia, such as acute heart failure, recent myocardial infarction. or shock, may increase the risk of lactic acidosis. · Care should be taken in patients with renal impairment. Renal function should be monitored throughout the therapy. If renal dysfunction is anticipated particularly in elderly patients, renal function should be assessed more frequently and drug should be discontinued if evidence of renal impairment is present as it may increase the chance of lactic acidosis. Dehydration may contribute to renal impairment. · Alcohol is known to potentiate the effect of metformin on lactate metabolism. Patients, therefore, should be warned against excessive alcohol intake while receiving XORMET XR. · XORMET XR should generally be avoided in patients with clinical or laboratory evidence of hepatic disease. · Driving: Diabetes Mellitus, its complications and the medications used to treat it, may affect a patient’s’ ability to drive safely. · Owing to the possibility of decreased vitamin B12 absorption, annual monitoring of vitamin B12 concentrations is advisable during long term treatment. · Safety and effectiveness of METFORMIN in pediatric patients under 18 years has not been established. · May also need to be temporarily stopped for examinations using contrast media in some patients (intravascular administration of iodinated contrast materials in radiologic studies can lead to renal failure, metformin should be discontinued prior to, or at the time of the test and not reinstituted until 48 hours afterwards, and only after renal function has been re-evaluated and found to be normal). · Should be discontinued in patients undergoing surgery and only restarted once normal renal function has been established.

Patients should consult with their physician before taking any medicine.

Skilax

DESCRIPTION:

The active ingredient in SKILAX is Sodium Picosulfate which is stool softening laxative taken orally.

INDICATIONS:

Constipation of any etiology and bowel clearance before surgery, childbirth or radiological investigations

DOSAGE AND ADMINISTRATION:

For Oral administration:

Unless and otherwise prescribed by doctors following dosages are recommended.

Adults and Children over 10 Years:

One to two 5 mL spoonful’s (5-10 mg) at night

Children under 10 Years:

Not to be taken by children under 10 years without medical advice.

Children (4-10 Years):

Half to one 5mL spoonful; (2.5 – 5mg) at night

Children under 4 Years:

The recommended dosage is 250 micrograms per kilogram body weight.

In the management of constipation once regularity has restarted dosage should be reduced and can be discontinued.

 Diluent:

Can be diluted with purified water

 PRESENTATION:

Skilax 5mg Tablets: Alu. Alu PVC. blister pack of 60

Skilax Drops: Pilfor proof plastic bottle of 15mL

Axesom

DESCRIPTION:

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar pharmacodynamic activity

COMPOSITION:

Each capsule contains: Esomeprazole 20mg (as Esomeprazole Magnesium Trihydrate in delayed release form). Esomeprazole 40mg (as Esomeprazole Magnesium Trihydrate in delayed release form).

INDICATIONS:

In combination with antibiotics in treatment of duodenal ulcer caused by Helicobacter pylori.

DOSAGE & ADMINISTRATION:

Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution, Impaired hepatic function Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg AXESOM should not be exceeded.

CONTRAINDICATIONS:

Known hypersensitivity to esomeprazole, substituted benzimidazoles or any other constituents of the formulation. Esomeprazole should not be used concomitantly with nelfinavir.

PRESENTATION:

1. Axesom 20mg Capsules: Blister pack of 2×7’s. 2. Axesom 40mg Capsules: Blister pack of 2×7’s.

Patients should consult with their physician before taking any medicine.

Inhibitol

DESCRIPTION:

Lansoprazole is a benzimidazole which specifically inhibits the H+/K+ ATP-ase (proton pump) of the parietal cells in the gastric mucosa.

COMPOSITION:

Each capsule contains Lansoprazole U.S.P. 30 mg in delayed release form.

INDICATIONS:

Healing and maintenance of duodenal ulcer, treatment of active benign gastric ulcer, healing of NSAIDs-associated gastric ulcer, risk reduction of NSAID-associated gastric ulcer, rhort term symptomatic treatment and maintenance of healing of gastro esophageal reflux disease(GERD), H. pylori eradication to reduce the risk of Duodenal Ulcer recurrence and for treatment of pathological hyper-secretory conditions like Zollinger Ellison syndrome.

DOSAGE & ADMINISTRATION:

Inhibitol should be taken once daily. To achieve the optimal acid inhibitory effect, and hence most rapid healing and symptom relief, lansoprazole should be administered in the morning before food. The capsules should be swallowed whole and not crushed or chewed. Duodenal ulcer: 30 mg daily for 4-8 weeks. Benign gastric ulcer: 30 mg daily for 8 weeks. Reflux esophagitis: 30 mg daily for 4-8 weeks, Zollinger Ellison syndrome: 60 mg daily to be continued till clinically indicated. Renal impairment: There is no need to alter the dosage in patients with impaired renal function. Hepatic impairment: The dose should not exceed 30 mg daily. Pregnancy: Inhibitol should be used only if clearly needed. Lactation: Animal studies indicate that lansoprazole is secreted into breast milk. However, breast-feeding should be discontinued if the use of lansoprazole is considered essential. Pediatric Use: The safety and effectiveness of lansoprazole in patients less than 1 year of age has not been established.

CONTRAINDICATIONS:

Hypersensitivity to lansoprazole.

UNDESIRABLE EFFECTS:

A low incidence of adverse events has been reported including; headache, diarrhea, abdominal pain, dyspepsia, nausea, vomiting, dry mouth, constipation, flatulence, dizziness, fatigue, rash, urticaria and pruritis.

PRESENTATION:

Inhibitol 30mg capsules: Blister pack of 1 x 14 capsules.

Patients should consult with their physician before taking any medicine.

Fosbu

DESCRIPTION:

Sofosbuvir is a hepatitis C virus (HCV) nucleotide analog NSSB polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.

COMPOSITION:

Fosbu 400mg Tablets: Each film coated tablet contains: Sofosbuvir 400mg.

INDICATIONS:

It is used in the treatment of chronic hepatitis C genotypes 1,2,3 or 4. It is given an oral dose of 400mg once daily in a combined regimen according to genotype. It should be considered when initiating treatment with Fosbu(Sofosbuvir); monotherapy of sofosbuvir is not recommended for treatment of chronic hepatitis C and the treatment regimen and the duration are dependent on both viral genotype and patient population.

DOSAGE & ADMINISTRATION:

An oral dose of one 400mg tablet Fosbu (Sofosbuvir) taken once daily with or without food. It should be used in combination with ribavirin or in combination with pegylated interferon and ribavirin for the treatment of chronic hepatitis C.

CONTRAINDICATIONS:

When used in combination with peginterferon aft/ribavirin or ribavirin alone, all contraindications to peginterferon alfa and/or ribavirin also apply to Fosbu (Sofosbuvir) combination therapy.

UNDESIRABLE EFFECTS:

The reported adverse events of sofosbuvir with ribavirin therapy and peginterferon alfa are fatigue, headache, nausea, insomnia, anemia, pruritus, asthenia, rash, decreased appetite, chills, influenza like illness, pyrexia, diarrhea, neutropenia, myalgia and irritability. The other reported adverse events are pancytopenia (particularly in subjects receiving concomitant pegylated interferon), severe depression (particularly in subjects with pre-existing history of psychiatric illness), including suicidal ideation and suicide. Laboratory changes include bilirubin elevation, creatine kinase elevation and lipase elevation.

PRESENTATION:

Fosbu 400mg Tablets

PREGNANCY & LACTATION:

Ribavirin may cause birth defects and fetal death; avoid pregnancy in female patients and female partners of male patients. Patients must have a negative pregnancy test prior to initiating therapy, use at least 2 effective non-hormonal methods of contraception and have monthly pregnancy tests.

Patients should consult with their physician before taking any medicine.

Omsta

DESCRIPTION:

Omsta (Omeprazole) is a proton pump inhibitor.

COMPOSITION:

Omsta 20mg Capsules: Each Capsule contains Omeprazole (as enteric coated pellets) …. 20mg Omsta 40mg Capsules: Each Capsule contains Omeprazole (as enteric coated pellets) …. 40mg

INDICATIONS:

  • Omsta (omeprazole) capsules is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks of therapy.
  • Omsta (omeprazole) capsule is indicated in Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence.
  • Omsta (omeprazole) is indicated for short term treatment (4 to 8 weeks) of active benign gastric ulcer in adults.
  • Omsta (omeprazole) is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 1 year of age and older.
  • Omsta (omeprazole) is indicated in pediatric patients 1 year of age to adults for short term treatment (4 to 8 weeks) of Erosive Esophagitis (EE) due to acid mediated GERD that has been diagnosed by endoscopy in patients 1 year of age and older.
  • Omsta (omeprazole) is indicated in pediatric patients 1 month to less than 1 year of age for short term treatment (up to 6 weeks) of EE due to acid mediated GERD.
  • Omsta is indicated for the long term treatment of pathological hypersecretory conditions (e.g Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

DOSAGE & ADMINISTRATION:

The recommended adult dosage regimen is:

  • Active duodenal ulcer: Osmta (Omeprazole) 20mg capsule once daily for 4 weeks.
  • Helicobacter pylori eradication: to reduce the risk of duodenal ulcer recurrence: In triple therapy treatment Omsta (Omeprazole) 20mg capsule in combination with amoxicillin 1000mg and Clarithromycin 500mg. Take all three drugs twice daily for 10 days. In patients with an ulcer present at the time of initiation of therapy, continue Omsta (omeprazole) 20mg once daily for another 18 days for ulcer healing and symptoms relief. It may be given as Omsta (omeprazole) 20mg capsule twice daily or 40mg once daily combined with amoxicillin 500mg and metronidazole 400mg both three times daily.
  • Active Benign Gastric Ulcer Omsta (omeprazole) 40mg capsule once daily for 4 to 8 weeks.
  • Treatment of symptomatic GERD Omsta (omeprazole) 20mg capsule once daily for 4 weeks.
  • Treatment of EE due to Acid Mediated GERD: Omsta (omeprazole) 20mg capsule once daily for 4 to 8 weeks.
  • Maintenance of healing of EE due to Acid Mediated GERD: Omsta (omeprazole) 20mg capsule once daily for up to 12 months.
  • Pathological hypersecretory conditions: The starting dose of Omsta (omeprazole) is 60mg once daily; adjust to patient needs, daily dosages of greater than 80mg should be administered in divided doses. Dosages up to 120mg three times daily have been administered, as long as clinically indicated. Some patients with Zollinger Ellison syndrome have been treated continuously for more than 5 years.

CONTRAINDICATIONS:

  •  It is contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis and urticarial.
  • Proton pump inhibitors (PPIs) including omeprazole, are contraindicated in patients receiving rilpivirine-containing products.

PRESENTATION:

1. Omsta 20mg Capsules: Blister Pack of 2×7’s tablets. 2. Omsta 40mg Capsules: Blister Pack of 2×7’s tablets.

Patients should consult with their physician before taking any medicine.

Daclata

DESCRIPTION:

Daclata (Daclatasvir) is an inhibitor of HCV nonstructural protein 5A (NS5A). Daclatasvir is freely soluble in water (>700 mg/mL).

COMPOSITION:

Daclata 30mg Tablets: Each film coated tablet contains: Daclatasvir dihydrochloride equivalent to daclatasvir ………. 30mg. Daclata 60mg Tablets: Each film coated tablet contains: Daclatasvir dihydrochloride equivalent to daclatasvir ………. 60mg.

INDICATIONS:

Daclata is indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection. It’s use is limited in: Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving daclatasvir in combination with sofosbuvir for 12 weeks.

DOSAGE & ADMINISTRATION:

The recommended dosage of Daclata is 60 mg, taken orally, once daily in combination with sofosbuvir for 12 weeks. Daclatasvir may be taken with or without food. The optimal duration of Daclatasvir and sofosbuvir for patients with cirrhosis has not been established. If sofosbuvir is permanently discontinued in a patient receiving Daclata with sofosbuvir, then Daclata should also be discontinued.

CONTRAINDICATIONS:

It is contraindicated in combination with drugs that strongly induce CYP3A and, thus, may lead to lower exposure and loss of efficacy of Daclatasvir. Contraindicated drugs include, Anticonvulsants drugs (phenytoin, carbamazepine, Antimycobacterial agents (rifampin), Herbal products St. John’s wort (Hypericum perforatum).

UNDESIRABLE EFFECTS:

The reported adverse events are; Serious symptomatic bradycardia, headache and fatigue, nausea and diarrhea. The laboratory abnormalities which includes transient, asymptomatic lipase elevations of greater than 3 times the upper limit of normal (ULN).

PRESENTATION:

Daclata 30mg tablets: Alu. Alu. blister pack of 4 x 7’s. Daclata 60mg tablets: Alu. Alu. blister pack of 4 x 7’s.

PREGNANCY & LACTATION:

No data with Daclatasvir in pregnant women are available to inform a drug-associated risk. No information regarding the presence of daclatasvir in human milk, the effects on the breastfed infant, or the effects on milk production is available. Daclatasvir is present in the milk of lactating rats. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Daclatasvir and any potential adverse effects on the breastfed infant from Daclatasvir or from the underlying maternal condition.

Patients should consult with their physician before taking any medicine.

Cidine

DESCRIPTION:

Cidine is pro-serotonergic and anti-dopaminergic  prokinetic.

COMPOSITION:

Cidine tablets contain Cinitapride (as acid tartrate)1 mg.

INDICATIONS:

Treatment of gastroesophageal reflux and functional gastrointestinal motility disorders.

DOSAGE & ADMINISTRATION:

1tablet, 3 times a day, 15 minutes before each meal.

CONTRAINDICATIONS:

Cinitapride is contraindicated in Hemorrhages, obstructions or perforations in whom stimulating gastric motility could be harmful.Proven tardive dyskinesia to neuroleptic drugs.

UNDESIRABLE EFFECTS:

Some patients may notice a slight sedation although Cinitapride has not shown sedation or changes in the psychometric tests of subjects taking the recommended doses. On rare occasion there may be extrapyramidal effects with spasms in the muscles of the face, neck and tongue, which disappear when the treatment is stopped. The following may appear on very rare occasions: Skin reactions: rash, pruritus,Gynecomastia.Very occasionally angioedema.

PRESENTATION:

Cidine 1 mg tablets: Blister pack of 1 x 10’s tablets.

PREGNANCY & LACTATION:

The physician must assess the risk/benefit ratio.

Patients should consult with their physician before taking any medicine.

Ulsanic

DESCRIPTION:

Ulsanic contains sucralfate, a non-systemic cytoprotective agent for the treatment of acid peptic disorders.

INDICATIONS:

Gastric and duodenal ulcer. Relapse prophylaxis of gastric and duodenal ulcer. Reflux esophagitis. Stress ulcer prophylaxis.

DOSAGE AND ADMINISTRATION:

Duodenal Ulcer:

2 Tablets Ulsanic 1 g twice a day or 2 teaspoonful Ulsanic (1 g susp.) twice a day.

Gastric Ulcer:

1 Tablet Ulsanic 1 g 3 to 4 times a day. Or 1 teaspoonful Ulsanic (1 g susp.) 3 to 4 times a day. 

Relapse Prophylaxis Of Gastric And Duodenal Ulcer:

2 Tablets Ulsanic 1 g once a day or 2 teaspoonful Ulsanic (1 g susp.) once a day.

Reflux Esophagitis:

1 Tablet ulsanic 1 g 4 times a day or 1 teaspoonful Ulsanic (1 g susp.) 4 times a day.

Stress Ulcer Prophylaxis:

1 tablet Ulsanic 1 g every 4 hours or 1 teaspoonful Ulsanic (1 g susp.) every 4 hours. 

For Short-term Treatment of Gastric and Duodenal Ulcer: 

1 g is taken before meals and the 4th dose in the evening at bedtime. Alternatively 2 g may be taken in the morning on rising and 2g in the evening at bedtime.

For Short-term Treatment Of Reflux Esophagitis:

1 g is taken after meals and at bedtime.

PRESENTATION:

Ulsanic 500mg Tablets: Pack of 20 tablets

Ulsanic 1g Tablets: Pack of 10 tablets

Ulsanic 1g Suspension: Bottle of 120 mL

Patients should consult with their physician before taking any medicine.

Tamadol

DESCRIPTION:

Tramadol hydrochloride are an opioid agonist. It is a centrally acting analgesic which possesses opioid agonist properties. The chemical name for tramadol hydrochloride is (±)cis-2-[(dimethylamino)methyl] -1-(3-methoxyphenyl) cyclohexanol hydrochloride.

INDICATIONS AND USAGE:

It is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve it for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]:

  • Have not been tolerated or are not expected to be tolerated.
  •  Have not provided adequate analgesia or are not expected to provide adequate analgesia.

DOSAGE AND ADMINISTRATION:

Initial Dosage:

Tamadol Capsule:

Start it at 25mg/day and titrated in 25mg increments as separate doses every 3 days to reach 100mg /day (25mg four times a day). Thereafter the total daily dose may be increased by 50mg as tolerated every 3 days to reach 200mg/day (50mg four times a day). After titration, it can be administered (50 to 100mg) as needed for pain relief every 4 to 6 hours not to exceed 400mg/day.

Tamadol Injection:

The usual dose is 50 or 100mg 4-6 hourly by the intravenous or intramuscular route. Dosage should be adjusted

according to pain severity and response. Intravenous injections must be given slowly over 2-3 minutes. For post-operative pain administer an initial bolus of 100mg. During the 60 minutes following the initial bolus, further doses of 50mg may be given every 10-20 minutes, up to a total dose of 250mg including the initial bolus. Subsequent doses should be 50mg or 100mg 4-6 hourly up to a total daily dose of 400mg.

STORAGE AND INSTRUCTIONS:

To be sold and used on the prescription of a registered medical practitioner only. Keep out of the reach of children. Do not store

above 30°C. After opening store between 2°C to 8°C and use within 24 hours. Keep in dry place. Protect from light.

It is contraindicated for:

  • All children younger than 12 years of age
  • Postoperative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy
  • Significant respiratory depression
  • Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
  • Known or suspected gastrointestinal obstruction, including paralytic ileus
  • Hypersensitivity to tramadol, any other component of this product or opioids
  • Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within the last 14 days
  • In patients suffering from acute intoxication with alcohol, hypnotics, analgesics, opioids, or psychotropic medicinal products
  • In patients with epilepsy not adequately controlled by treatment
  • For use in narcotic withdrawal treatment

Patients should consult with their physician before taking any medicine.

Hilin

BRAND NAME:

Hilin 

GENERIC NAME:

Pregabalin

DESCRIPTION

Hilin (Pregabalin) is a prescription medicine used to: Neuropathic pain 

PRECAUTIONS:

Tell your healthcare provider about all your medical conditions, including if you: have or have had depression, mood problems or suicidal thoughts or behavior, have kidney problems or get kidney dialysis, have heart problems including heart failure, have a bleeding problem or a low blood platelet count, have abused prescription medicines, street drugs, or alcohol in the past.

DOSAGE AND ADMINISTRATION:

Take Hilin exactly as your doctor tells you. Hilin can be taken with or without food. 

INDICATIONS:

Nueropathic Pain, Low back Pain, Post herpetic Neuralgia, Epilepsy

CONTRAINDICATIONS:

Hypersensitivity to the active substance or to any of the excipients

ADVERSE EVENTS:

The most commonly reported adverse reactions were dizziness and somnolence, increased appetite, euphoric mood, confusion, decreased libido, irritability, ataxia, disturbance in attention, abnormal coordination and memory impairment.

PRESENTATION:

Hilin is presented in 50mg, 75mg, 100mg, 150mg capsules

STORAGE:

Do not store above 30°C. Keep in a dry place. Protect from light.

Patient should consult with their physician before taking any medicine.

Hiloric

DESCRIPTION:

Hiloric, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid by selectively inhibiting xanthine oxidase, which is needed to make uric acid in the body. By reducing the production of uric acid, Hiloric (Febuxostat) can reduce levels of uric acid in the blood and keep them low, stopping crystals from building up. This can reduce the symptoms of gout. Hiloric (Febuxostat) is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.

COMPOSITION:

Hiloric 40mg Tablets Each film coated tablet contains: Febuxostat 40mg Hiloric 80mg Tablets Febuxostat 80mg

INDICATIONS:

Hiloric (Febuxostat) is a xanthine oxidase (XO) inhibitor indicated for chronic management of hyperuricemia in patients with chronic gout. Hiloric (Febuxostat) is not recommended for the treatment of asymptomatic hyperuricemia.

DOSAGE & ADMINISTRATION:

For treatment of hyperuricemia in patients with gout, Hiloric (Febuxostat) is recommended at 40mg or 80mg once daily. The recommended starting dose of Hiloric (Febuxostat) for the treatment of hyperuricemia in patients with gout is 40mg once daily. For patients who do not achieve a serum uric acid (sUA) less than 6 mg/dL after two weeks with 40 mg, Hiloric (Febuxostat) 80 mg is recommended. Hiloric (Febuxostat) can be taken without regard to food or antacid use.

CONTRAINDICATIONS:

Febuxostat is contraindicated in patients with; Hypersensitivity to the active substance or to any of the excipients. In patients being treated with Azithromycin or Mercaptopurine. Asymptomatic hyperuricemia.

PRESENTATION:

1. Hiloric 40mg Tablets: Alu Alu Blister Pack of 2×10’s. 2. Hiloric 40mg Tablets: Alu Alu Blister Pack of 2×10’s.

Patients should consult with their physician before taking any medicine.

Airtal

DESCRIPTION:

Airtal is a non-steroidal agent with excellent anti-inflammatory and analgesic properties.

COMPOSITION:

Airtal 100 mg film coated tablet contains aceclofenac 100 mg.

INDICATIONS:

Airtal is indicated in the management of acute and chronic painful and inflammatory processes such as rheumatoid arthritis, osteoarthritis, arthrosis, ankylosing spondylitis, cervicalgia, lumbago, tendinitis, sprains and scapulo-humeral periarthritis. Airtal is also indicated in the treatment of painful processes of various etiologies such as odontalgia, lumbosciatica, myalgia, post-episiotomy pain, postlabour pain, and primary dysmenorrhea.

DOSAGE & ADMINISTRATION:

The recommended daily dose is one tablet every 12 hours (200 mg/day). Tablets should be taken with a little water. Dosage in hepatic impairment: The dose should be reduced to 100 mg daily in patients with hepatic impairment.

CONTRAINDICATIONS:

Aceclofenac should not be administered to patients with gastrointestinal bleeding or with active or suspected peptic ulcer.

UNDESIRABLE EFFECTS:

The majority of side effects observed, have been mild and reversible and include gastrointestinal disorders (flatulence, abdominal pain, nausea and diarrhoea) and occasional occurrence of dizziness. Dermatological complaints, including pruritus and rash, as well as abnormal hepatic enzyme levels and raised serum creatinine, have occasionally been reported.

PRESENTATION:

Airtal 100 mg tablets: Pack of 10 X 2 tablets.

Patients should consult with their physician before taking any medicine.

Cyrocin

DESCRIPTION:

Cyrocin is a synthetic broad spectrum antimicrobial agent for oral and IV administration.

COMPOSITION

Cyrocin 250mg Tablet: 

Each film-coated tablet contains: Ciprofloxacin (as Hydrochloride) 250mg

Cyrocin 500mg Tablets: Each film-coated tablet contains: Ciprofloxacin (as Hydrochloride) 500mg. 

Cyrocin 125mg Dry Powder for Suspension : Each 5mL of reconstituted suspension contains: Ciprofloxacin (as Hydrochloride) 125mg

Cyrocin 250mg Dry Powder for Suspension: Each 5mL of reconstituted suspension contains: Ciprofloxacin (as Hydrochloride) 250mg

INDICATIONS:

Adults: 

Ciprofloxacin is indicated in Urinary Tract Infections, Acute Uncomplicated Cystitis in females, Chronic Bacterial Prostatitis, Lower Respiratory Tract Infections, Acute Sinusitis, Skin and Skin Structure Infections, Complicated Intra-Abdominal Infections (used in combination with metronidazole), Infectious Diarrhea, Uncomplicated cervical and urethral gonorrhea.

DOSAGE AND ADMINISTRATION:

The duration of treatment depends upon the severity of infection. The usual duration is 7 to 14 days; however, for severe and complicated infections more prolonged therapy may be required.

CONTRAINDICATIONS:

Ciprofloxacin is contraindicated in persons with a history of hypersensitivity to Ciprofloxacin, any member of the quinolone class of antimicrobial agents, or any of the product components. Concomitant administration with tizanidine is contraindicated.

PRESENTATION:

Cyrocin 250mg and 500mg are available in blister packing of 10’s

Cyrocin IV 200mg per 100 mL solution is available in the packing of 1’s

PREGNANCY AND LACTATION:

Should be used during pregnancy only if the potential benefit justifies the potential risk of the fetus. The drug should be used only after taking into account the benefits offered and the potential risks involved.

Patients should consult with their physician before taking any medicine.

Efix

DESCRIPTION:

Efix is a semi synthetic third generation cephalosporin antibiotic for oral administration. Bacterial action of Efix results from inhibition of cell-wall synthesis. Efix is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins due to presence of beta-lactamase may be susceptible to Efix.

COMPOSITION:

Efix Capsules Each Capsule Contain: Cefixime (as trihydrate) USP 400mg Efix Dry Suspension (when reconstituted as directed) Each 5ml contains: Cefixime (as trihydrate) USP 100mg Efix DS Dry Suspension (when reconstituted as directed) Each 5ml contains: Cefixime (as trihydrate) USP 200mg

INDICATIONS:

Efix (Cefixime) is an orally active Cephalosporin antibiotic, which has marked in vitro bactericidal activity against wide range of Gram positive and Gram negative organisms. It is indicated for the treatment of acute infection caused by susceptible micro organisms in Upper Respiratory Tract Infection (URTI), Otitis Media, Sinusitis, Pharyngitis, Tonsillitis, Lower Respiratory Tract Infection (LRTI), Bronchitis, Urinary Tract Infection (UTI), Cystitis, Cystourethritis Uncomplicated Pyelonephritis and Uncomplicated Gonorrhea (Cervical/Urethral, Rectal and Pharyngeal)

DOSAGE & ADMINISTRATION:

The usual course of treatment is 5-14 days depending upon the severity of infection. Adults and Children over 12 years: The recommended dose is one capsule of 400mg daily administered as a single dose. As a general rule, for prescribing in children the following daily wise in terms of volume of oral suspension are suggested. Age Efix Susp (Daily as a single dose) Efix DS Susp (Daily as a single dose) 1 – 4 years 5ml (one spoonful) 2.5ml (half spoonful) 5 – 9 years 10ml (two spoonful) 5ml (one spoonful) 10 – 12 years 15ml (three spoonful) 7.5ml (one & half spoonful)

CONTRAINDICATIONS:

Patients with known hypersensitivity to Cephalosporin.

PRESENTATION:

1. Efix Capsules 400mg. Available in Alu/Alu blister pack of 1×5 capsules. 2. Efix Dry Suspension 100mg/5ml. Available in a pack of 30ml. 3. Efix DS Dry Suspension 200mg/5ml. Available in a pack of 30ml.

Patients should consult with their physician before taking any medicine.

Azipos

DESCRIPTION:

Azipos (Azithromycin) is a nitrogen-containing macrolide (azalide)

COMPOSITION:

Azipos 250mg Capsule

Each capsule contains: Azithromycin (as Dehydrate) 250mg

Azipos 500mg Capsule

 Each capsule contains: Azithromycin (as Dehydrate) 500mg

INDICATIONS:

Acute bacterial exacerbations of chronic bronchitis, otitis media, Pharyngitis & tonsillitis, uncomplicated skin and skin structure infections, mild to moderate typhoid due to multiple antibacterial resistant organisms, community acquired pneumonia with low to moderate severity, community acquired pneumonia with high severity, antibacterial prophylaxis for insertion of intrauterine device, prevention of secondary case of invasive group a streptococcal infection in patients who are allergic to penicillin, uncomplicated Gonorrhea, Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhea and Genital ulcer disease in men due to Haemophilus ducrevi (chancroid).

DOSAGE AND ADMINISTRATION:

In acute bacterial exacerbations of chronic bronchitis: 500 mg once daily for 3 days or 500 mg as a single dose on day 1, followed by 250 mg once daily on days 2 through 5. In acute bacterial sinusitis: 500 mg once daily for 3 days. In pharyngitis/tonsillitis (second line therapy): 500 mg as a single dose on day 1, followed by 250 mg once daily on days 2 through 5. In otitis media: 500 mg once daily for 3 days; Alternatively, initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days. In uncomplicated skin and skin structure infections: 500 mg as a single dose on day 1, followed by 250 mg once daily on days 2 through 5. In mild to moderate typhoid due to multiple antibacterial resistant organisms: Adult Dose; 500 mg once daily for 7 days. Child 6 months and over: 10 mg/kg (to a maximum of 500 mg) once daily for 7 days. In community acquired pneumonia, low to moderate severity: 500 mg once daily for 3 days.

 Alternatively, initially 500 mg once daily for 1 day, then 250 mg once daily for 4 days. In community acquired pneumonia, high severity: Initially 500 mg once daily intravenously for at least 2 days, then 500 mg once daily for a total duration of 7-10 days. In antibacterial prophylaxis for insertion of intrauterine device: one single 1000 mg dose. In prevention of secondary case of invasive group, a streptococcal infection in patients who are allergic to Penicillin: Child 6 months to 11 years, 12 mg/kg once daily (maximum per dose 500 mg) for 5 days. Child 12-17 years & Adult, 500 mg once daily for 5 days. In uncomplicated Gonorrhea: one single 1000 mg dose. In urethritis and cervicitis: one single 1000 mg dose. In genital ulcer disease in men (chancroid): one single 1000 mg dose. The pediatric dose in respiratory tract infections, otitis media, skin and soft tissue infections: Child 6 months to 17 years: 10 mg/kg once daily (maximum per dose 500 mg) for 3 days. Child 6 months to 17 years (body weight 15-25 kg):200 mg once daily for 3 days. Child 6 months to 17 years (body weight 26-35 kg): 300mg once daily for 3 days. Child 6 months to 17 years (body weight 36-45 kg): 400 mg once daily for 3 days.

CONTRAINDICATIONS:

It is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin or any macrolide or ketolide drug. It is contraindicated in patients with history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.

Voxiquin

DESCRIPTION:

Levofloxacin is the fluoroquinolone antibiotic.

COMPOSITION:

250 & 500mg film coated tablets. Each film coated tablet contains Levofloxacin 250mg and 500mg.

INDICATIONS:

Indicated for the treatment of adults with mild, moderate and severe infections caused by pathogens sensitive to Levofloxacin; Acute Maxillary Sinusitis, Acute Exacerbation of Chronic Bronchitis, Nosocomial Pneumonia, Community Acquired Pneumonia, Complicated and Uncomplicated Skin and Soft Tissue Infections, Complicated and Uncomplicated Urinary Tract Infections, Acute Pyelonephritis and Chronic Bacterial Prostatitis.

DOSAGE & ADMINISTRATION:

Acute Maxillary Sinusitis (500mg/day for 10-14 days), Acute Exacerbation of Chronic Bronchitis (500mg/day for 7 days), Nosocomial Pneumonia (750mg/day for 7-14 days),Community Acquired Pneumonia (500mg/day for 7-14 days), Uncomplicated Skin and Soft Tissue Infections (500mg/day for 7-10 days), Complicated Skin and Soft Tissue Infections (750mg/day for 7-14 days), Complicated Urinary Tract Infections & pyelonephritis (250mg/day for 10 days), Uncomplicated Urinary Tract Infections (250mg/day for 3 days), Chronic Bacterial Prostatitis (500mg/day for 28 days).

CONTRAINDICATIONS:

Levofloxacin is contraindicated in patients with known hypersensitivity of Levofloxacin, quinolone antimicrobial agents or any other component of the product.

PRESENTATION:

Voxiquin tablets are available as film coated tablets of 250mg and 500mg in pack of 10’s each.

Patients should consult with their physician before taking any medicine.

Artecxin

COMPOSITION:

Artecxin Dispersible Tablet: Each dispersible tablet contains 

Artemether 20mg and Lumefantrine 120mg

Artemether 40mg and Lumefantrine 240mg

Artemether 80mg and Lumefantrine 480mg

INDICATIONS:

Artecxin is indicated for adults and children with acute, uncomplicated infections due to Plasmodium falciparum or mixed infections including P. falciparum.

CONTRAINDICATIONS:

Patients with hypersensitivity to the active substances or to any of the excipients and patients with severe malaria.

PRESENTATION:

Artecxin Dispersible Tablets: Blister pack of 2 X 8’s tablets

Artecxin Forte Dispersible Tablets: Blister pack of 2 X 4’s tablets

Artecxin Plus Tablets: Blister pack of 2 X 3’s tablets

PREGNANCY AND LACTATION:

Treatment with artemether/lumefantrine should only be considered if the potential benefits to mother outweighs the risk to the fetus. It should not be given to a nursing woman as it is excreted in the breast milk.

Patients should consult with their physician before taking any medicine.

Oxaquin

DESCRIPTION:

Each Oxaquin film coated tablet contains Moxifloxacin 400mg

INDICATIONS:

Oxaquin is Indicated for the treatment of infections caused by susceptible strains of bacteria which cause acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, community acquired pneumonia, uncomplicated skin and skin structure infections .Appropriate culture and susceptibility tests should be performed before treatment in order to Isolate and identify organisms causing Infections and to determine their susceptibility to Moxifloxacin.

DOSAGE & ADMINISTRATION:

The dose of Oxaquin is 400mg (orally) once every 24 hours. The duration of therapy depends on the type of Infection.

CONTRAINDICATIONS:

Hypersensitivity to Moxifloxacin or any member of the quinolone class of antimicrobial agents.

PRESENTATION:

Oxaquin tablets 400mg Blister pack of 5 tablets.

Patients should consult with their physician before taking any medicine.

Tres Orix Forte

DESCRIPTION:

Apetite Stimulant

COMPOSITION:

Each 5ml spoon of Tres-orix FORTE contains: Cyproheptadine orotate 1.5 mg, Carnitine HCL 150 mg, Lysine HCL 150 mg, Vitamin B1 10 mg, Vitamin B6 10 mg, Vitamin B12 100 mcg.

INDICATIONS:

Anorexia in children, adolescents and adults. Post infection anorexia. Retardation in growth, habitual vomiting (excluding when of an organic origin). Emotional instability when accompanied by anorexic crises. Constitutional thinness.

DOSAGE & ADMINISTRATION:

Adults: 1 tablespoonful twice daily before meals. Children: Infants: 2 teaspoonful of 2.5ml twice daily, 2 to 6 years old: 2 teaspoonful of 5ml twice daily, From 7 to 12 years old: 1 teaspoon of 5ml thrice daily. The appearance of drowsiness is a good sign for calculating the dosage, and is even desirable to appear slightly in nervous children, as their psychic condition improves simultaneously. However, drowsiness tends to disappear a few days after beginning of treatment. The effects of treatment are usually observed between 4 to 10 days after administration is initiated. Treatment can be administered for periods of one two months with rest periods of 15 days to one month, without any undesirable side effects having been noticed or any alteration of the humoral constants.

CONTRAINDICATIONS:

Hypersensitivity to the components. Glaucoma. predisposition to urine retention. newborns. INCOMPATIBILTIES: Tres-Orix Forte should not be administered simultaneously with other medicines which are Central Nervous System depressants.

PRESENTATION:

Bottle of120 ml. FURTHER PRESCRIBING INFORMATION AVAILABLE ON REQUEST.

Patients should consult with their physician before taking any medicine.

Leviva

DESCRIPTION:

Levocetirizine dihydrochloride, is an orally active H1- receptor antagonist. Levocetirizine the active enantiomer of cetirizine is an antihistamine; its principal effects are mediated via selective inhibition of H1 receptors. 

COMPOSITION:

Leviva 5mg Tablet:

Each film-coated tablet contains: Levocetirizine Dihydrochloride 5mg

Leviva 2.5mg/5mL Syrup:

Each 5mL syrup contains: Levocetirizine Dihydrochloride 2.5mg

INDICATIONS:

  • Leviva (Levocetirizine) is indicated for the relief of symptoms associated with perennial allergic rhinitis in children 6 months to 2 years of age. 
  • Leviva (Levocetirizine) is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older.

DOSAGE AND ADMINISTRATION:

It can be taken without regard of food consumption. 

Perennial Allergic Rhinitis:

Children 6 months to 2 years of age: The recommended initial dose of Leviva (Levocetirizine) is half teaspoon oral solution 1.25mg (2.5)mL once daily in the evening. The 1.25mg once daily dose should not be exceeded based on comparable exposure to adults receiving 5mg.

Chronic Idiopathic Urticaria:

Adults and children 12 years of age and older: The recommended dose of Leviva (Levocetirizine) is one tablet 5mg or 2 teaspoons (10mL) oral solution once daily in the evening. 

Children 6 to 11 years of age:

The recommended dose of Leviva (Levocetirizine) is half tablet 2.5mg or 1 teaspoon (5mL) oral solution once daily in the evening.

Children 6 months to 5 years of age:

The recommended initial dose of Leviva (Levocetirizine) is half teaspoon 1.25 mg oral solution (2.5mL) once daily in the evening. 

Dose Adjustment for Renal and Hepatic Impairment:

In adults and children 12 years of age and older with:

  • Mild renal impairment (creatinine clearance [CLCR] = 50 – 80 mL/min; a dose of 2.5mg once daily is recommended. 
  • Moderate renal impairment (CLCR = 30 – 50 mL/min) a dose of 2.5mg once every other day is recommended.
  • Severe renal impairment; (CLCR = 10-30mL/min) a dose of 2.5 mg twice weekly is recommended (once every 3 to 4 days).
  • End stage renal disease patients: (CLCR = <10 mL/min) and patients undergoing hemodialysis should not receive Levocetirizine.

CONTRAINDICATIONS:

Levocetirizine is contraindicated in:

  • Patients with known hypersensitivity to Levocetirizine or any of the ingredients of Leviva or to cetirizine. Observed reactions range from urticaria to anaphylaxis. 
  • Patients with end stage renal disease
  • Children 6 months to 11 years of age with impaired renal function.

PRESENTATION:

1. Leviva 5mg Tablets: Blister Pack of 10’s tablets

2. Leviva 2.5mg/5mL Syrup: Bottle of 60mL Syrup.

 

Kestine

COMPOSITION:

Kestine 10mg contains 10mg of Ebastine. Kestine 20mg contains 20mg Ebastine. Each 5ml Kestine liquid contains 5mg Ebastine. DESCRIPTION: Ebastine has clinically significant anti-histaminic effects. Ebastine produces a rapid, intense and long lasting inhibition of peripheral H1-receptors, devoid of untoward CNS actions and anti-cholinergic effects. No significant increase in sedation at the recommended dose of up to 20 mg has been observed.

INDICATIONS:

Ebastine is indicated for the symptomatic treatment of allergic rhinitis (seasonal and perennial), whether or not associated with allergic conjunctivitis, and chronic urticaria.

DOSAGE & ADMINISTRATION:

Adults & children above 12 years: 1 tablet (10 mg) or 2(5 ml) teaspoonfuls of liquid once daily. In severe symptoms 1 tablet 20 mg or 4 (5 ml) teaspoonfuls of liquid once daily. Children: 6 to 11 years: one teaspoonfuls dose (5 ml equivalents to 5 mg) once daily. Children: 2 to 5 years: One half teaspoon dose (2.5 ml equivalent to 2.5 mg) once daily. There is no need for the dosage adjustment in patients with mild to moderate liver function disorders.

CONTRAINDICATIONS:

Patients with a known hypersensitivity to Ebastine or any of the tablets & liquid ingredients.

PRESENTATION:

Kestine is available in 10 mg & 20 mg tablets in packs of 1×10’s tablets each. Kestine Liquid in a glass bottle of 30 ml with graduated spoon.

Patients should consult with their physician before taking any medicine.

Combivair

DESCRIPTION:

Combivair Rotacaps is a combination of budesonide, a potent glucocrticoid and formoterol, a selective long-acting beta -agonist. 2 Budesonide is a potent glucocorticoid that binds with high affinity to the glucocorticoid receptor. It has a high ratio of topical to systemic activity. Formoterol is a very potent long-acting beta -agonist with a high intrinsic 2 activity and a rapid onset of action.

COMPOSITION:

Combivair 200 Rotacaps: Each capsule contains: Budesonide B.P. 200 mcg Formoterol Fumarate (as Dihydrate) B.P. 6 mcg Combivair 400 Rotacaps: Each capsule contains: Budesonide B.P. 400 mcg Formoterol Fumarate (as Dihydrate) B.P. 6 mcg

INDICATIONS:

Combivair Rotacap is indicated in the regular treatment of asthma, where use of a combination (long acting beta -agonist and inhaled 2 corticosteroid) has been found to be appropriate. Symptomatic treatment of severe chronic obstructive pulmonary disease (COPD) with a history of repeated exacerbations despite regular therapy with long acting bronchodilators. It is not indicated for the relief of acute bronchospasm.

DOSAGE & ADMINISTRATION:

Capsules are intended for use through Revolizer or Rotahaler only and are not to be swallowed. Dosage is individual and adjusted according to disease severity. When control has been achieved, the dose should be titrated to the lowest effective dose, which could include Combivair Rotacap given once daily.

CONTRAINDICATIONS:

Combivair Rotacap is contraindicated in patients with a history of hypersensitivity to any of the component of the drug product.

PRESENTATION:

1. Combivair 200 Rotacaps: Blister pack of 3 X 10’s Rotacaps.
2. Combivair 400 Rotacaps: Blister pack of 3 X 10’s Rotacaps.

Patients should consult with their physician before taking any medicine.

Tiovair

DESCRIPTION:

It is a synthetic, non-chiral, quaternary ammonium compound. It is sparingly soluble in water and soluble in methanol. The dry powder formulation within the Tiovair capsule is intended for oral inhalation only. The drug substance, tiotropium bromide monohydrate, is an anticholinergic with specificity for muscarinic receptors.

COMPOSITION:

Tiovair Rotacaps: Each capsule contains: Tiotropium (as Bromide Monohydrate) 18 mcg

INDICATIONS:

Tiovair is indicated as a long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations.

DOSAGE & ADMINISTRATION:

For oral Inhalation only Inhalation of the powder contents of a single TIOVAIR capsule (18 mcg) once daily CONTRAINDICATIONS Hypersensitivity to tiotropium, ipratropium or any components of Tiovair capsules

CONTRAINDICATIONS:

Tiotropium bromide inhalation powder is contraindicated in patients with hypersensitivity to tiotropium, atropine or its derivatives, e.g. ipratropium or oxitropium or to the excipient lactose monohydrate.

PRESENTATION:

Available as dry powder inhalation capsules. Tiovair: Tiotropium 18 mcg Each sale pack contains 20 dry powder inhalation capsules.

Patients should consult with their physician before taking any medicine.

Breavent

DESCRIPTION:

Salbutamol is a short-acting β -adrenergic receptor agonist and the tertiary butyl group in salbutamol (or albuterol) makes it more selective for β receptors. Salbutamol is beta adrenergic stimulant which has a highly selective action on the receptors in bronchial muscle resulting in bronchodilatation.

COMPOSITION:

Breavent 200 Rotacaps: Each capsule contains: Salbutamol (as sulphate) B.P. 200 mcg.

INDICATIONS:

Breavent Rotacaps are indicated for the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor. It is also used for the prevention of exercise-induced bronchospasm

DOSAGE & ADMINISTRATION:

Breavent Rotacaps are for inhalation use only through Rotahaler. For relief of acute episodes of bronchospasm: Adults One or two capsules as single dose. The maximum daily dose is 800mcg in a day. Children One capsule as a single dose. The maximum daily dose is 400mcg in a day. To prevent allergen or exercise induced bronchospasm: Adults 2 capsules (400 mcg) should be taken 15 minutes before exercise.

CONTRAINDICATIONS:

Hypersensitivity to any of the components of the formulation.

PRESENTATION:

Breavent Rotacaps 200 mcg: Bottle of 30 capsules

Patients should consult with their physician before taking any medicine.

Montit

DESCRIPTION:

Montelukast sodium, the active ingredient in Montit, is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl leukotriene CysLT1 receptor.

COMPOSITION:

Montit 5mg Chewable Tablet: Each chewable tablet contains: Montelukast Sodium 5mg 

Montit 10mg Film-coated Tablet: Each film coated-tablet contains: Montelukast Sodium 10mg

INDICATIONS:

Asthma Montit (Montelukast) is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. Exercise-induced Bronchoconstriction (EIB) Montit (Montelukast) is indicated for prevention of exercise-induced bronchoconstriction (EIB) in patients 6 years of age and older. Allergic Rhinitis Montit (Montelukast) is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial rhinitis in patients 6 months of age and older.

DOSAGE AND ADMINISTRATION:

  • The dosage of Montit (Montelukast) for adults and adolescents 15 years of age and older with asthma, is one 10mg tablet daily to be taken in the evening.
  • The dosage of Montit (Montelukast) for patients 6 to 14 years of age, is 5mg chewable tablet to be taken in the evening. Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. Exercise-Induced Bronchoconstriction (EIB).
  • The dosage of Montit (Montelukast) for adults and adolescents 15 years of age and older with EIB, is one 10mg tablet daily to be taken in the evening. For prevention of EIB, a single dose of Montit 10mg should be taken at least 2 hours before exercise.
  • The dosage of Montit (Montelukast) for patients 6 to 14 years of age, is 5mg chewable tablet to be taken in the evening. Allergic Rhinitis
  • The dosage of Montit (Montelukast) for adults and adolescents 15 years of age and older is one 10mg tablet daily to be taken in the evening, without regard to time of food ingestion.
  • The dosage of Montit (Montelukast) for patients 6 to 14 years of age, is 5mg chewable tablet to be taken in the evening.
  • Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established. Perennial Allergic Rhinitis.
  • The dosage of Montit (Montelukast) for adults and adolescents 15 years of age and older is one 10mg tablet daily to be taken in the evening, without regard to time of food ingestion.
  • The dosage of Montit (Montelukast) for patients 6 to 14 years of age, is 5mg chewable tablet to be taken in the evening.
  • Safety and effectiveness in pediatric patients less than 12 months of age with asthma have not been established.

CONTRAINDICATIONS:

Hypersensitivity to any component of this product.

PRESENTATION:

Montit 5mg Chewable Tablets: Blister Pack of 2 X 7’s tablets

Montit 10mg Film-coated Tablets: Blister Pack of 2 X 7’s tablets

Patients should consult with their physician before taking any medicine.

Prostam

DESCRIPTION:

Tamsulosin hydrochloride is an alpha1- adrenoceptor blocking agent in Prostate.

COMPOSITION:

Prostam contains Tamsulosin HCl 0.4mg / Sustained-eleased Capsules

INDICATIONS:

LUTS (Lower Urinary Tract Symptoms) associated with BPH (Benign Prostatic Hyperplasia)

DOSAGE AND ADMINISTRATION:

In benign prostatic hyperplasia the Prostam capsule is given orally in a modified-release formulation in a dose of 0.4 mg once daily. The dose may be increased after 2 to 4 weeks, if necessary, to 0.8 mg once daily.

CONTRAINDICATIONS:

Prostam capsule is contraindicated in patients with; Known hypersensitivity to Tamsulosin hydrochloride or any of its components, History of orthostatic hypotension, taking other alpha adrenergic blocking agents, severe hepatic insufficiency.

PRESENTATION:

Prostam 0.4mg Capsules: Blister pack of 2 x 14’s capsules.

Patients should consult with their physician before taking any medicine.

expand_less